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ABSTRACT 
Javier Rivera Guzman 
 
THE INHIBITOR-OF-APOPTOSIS PROTEIN SURVIVIN INCREASES P34CDC2 
PHOSPHORYLATION AND ENHANCES CELL SURVIVAL AND 
PROLIFERATION BY PROTECTING THE WEE1 KINASE FROM DEGRADATION 
BY CASPASE-3 
 
The anti-apoptotic protein Survivin and the cyclin-dependent kinase p34Cdc2 are 
involved in cell cycle progression and apoptosis.  Activation of Cdc2 is required for its 
pro-apoptotic activity, which can be inhibited by phosphorylation at Tyrosine-15 (Tyr15).  
In transduced IL-3-dependent murine BaF3 hematopoietic cells, over-expression of wild-
type-(wt)-Survivin increased Cdc2-Tyr15 phosphorylation, while over-expression of a 
dominant-negative-(dn)-T34A-Survivin construct decreased its phosphorylation.  The 
increased phospho-Tyr15 levels associated with ectopic Survivin directly correlated with 
enhanced BaF3 cell survival in the absence of growth factors, and low phospho-Tyr15 
levels observed in cells expressing ectopic dn-Survivin correlated with decreased 
survival.  BaF3 cells transduced with Internal Tandem Duplication (ITD) mutations of 
the Flt3 receptor that results in increased Survivin levels, also contained increased levels 
of Tyr15 phosphorylated Cdc2.  In BaF3 cells over-expressing wt-Survivin, 2-fold higher 
levels of Wee1 protein were observed compared to cells expressing control vector alone.  
 vii 
 
Treatment of control BaF3 cells with the caspase-3 inhibitor Ac-DEVD-CHO increased 
both Cdc2-Tyr15 phosphorylation and Wee1 protein levels.  In a similar fashion over-
expression of wt-Survivin in these cells maintained high levels of Tyr15 phosphorylated 
Cdc2 and Wee1 protein.  In MCF7 human breast cancer cells that lack caspase-3, 
increase of Tyr15 phosphorylated Cdc2 and Wee1 kinase protein by caspase-3, -7 or a 
pan-caspase inhibitor was absent, linking Survivin and caspase-3 to the increase of Wee1 
and Tyr15 phosphorylation of Cdc2.  To further link Survivin and Cdc2, we treated cells 
with AICAR and 17-AAG that inhibit Hsp90, which is known to be required for Survivin 
stability.  Treatment of BaF3 cells expressing wt-Survivin with AICAR and 17-AAG 
decreased Cdc2-Tyr15 phosphorylation compared to vehicle-treated control cells.  Taken 
together, these results indicate that Survivin protects the Cdc2-Tyr15-targeting kinase 
Wee1 from degradation by caspase-3 which leads to increased inhibitory Cdc2-Tyr15 
phosphorylation resulting in reduced apoptosis and enhanced survival. 
 
 
Louis M. Pelus, Ph.D. 
Committee Chairman 
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INTRODUCTION 
Survivin 
Structure and Function 
 Survivin is a member of the inhibitor of apoptosis (IAP) family of endogenous 
anti-apoptotic proteins characterized by the presence of a baculoviral inhibitor of 
apoptosis repeat (BIR) domain [1, 2] that inhibits caspase activity.  Survivin was 
originally found to be highly expressed in cancer and fetal tissues but absent in 
differentiated adult tissues.  However, more recent studies show that Survivin is 
expressed in a number of non-terminally differentiated adult tissues particularly those 
characterized by a high degree of proliferation and/or self-renewal such as hematopoietic 
stem cells, neuronal stem cells, keratinocyte stem cells [3-6] and T-cells.  In mice, 
Survivin is also known as thymus/testis-specific IAP (TIAP) [7].  Survivin plays a 
regulatory role in both evasion of apoptosis and cell cycle progression [8].  Survivin 
expression is highly upregulated in virtually all solid tumors and leukemias and is usually 
associated with more aggressive disease and resistance to chemotherapy [9].  The fact 
that Survivin is highly over-expressed in cancer cells with limited expression in normal 
tissues has made it an attractive target for cancer therapy [10].  Although Survivin can 
provide cells with a proliferative advantage, its over-expression alone does not appear 
sufficient to confer growth factor-independence or transformation [7, 11, 12]. 
 The Survivin gene (Birc5) is approximately 14.7 kilobases in length and has been 
localized to chromosome 17q25 [13].  It contains a TATA-less promoter rich in Sp1 
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binding sites, which are required for basal gene transcription [14, 15].  This gene encodes 
a wild-type Survivin protein that is approximately 16.5 kilodaltons in size and forms a 
homodimer which is thought to be necessary for its antiapoptotic function [16, 17].  
Phosphorylation of Threonine-34 by the Cdc2/Cyclin B1 heterodimeric kinase is believed 
to be necessary for Survivin dimerization [18].  Survivin has a number of known direct 
binding partners including CRM1, Smac/DIABLO, INCENP, Borealin, Aurora kinase B 
and Hsp90 [19-24].  Figure 1 shows an overview of the protein structure and protein-
protein interactions of wild-type Survivin [10].   
Splice Variants 
To date approximately 14 splice variants of the Survivin gene have been reported 
including Survivin, 2B, Ex3, 3B and 2α [9].  Figure 2 shows the exon splicing of wild-
type Survivin and the variants 2α, 2B, Ex3 and 3B [10, 25].  These variants have been 
reported to exhibit differing functions with different subcellular localizations [26, 27].  
Whereas variants Ex3 and 3B are considered to be anti-apoptotic, similar to wt- 
Survivin (albeit 3B is reported to be more potent than Ex3), variants 2B and 2α are 
considered to be pro-apoptotic, although this is still in debate and some investigators 
prefer to term it “non-antiapoptotic” [28, 29].  Our laboratory has also identified two 
novel splice variants, Survivin 3G and 3G-variant that have anti-apoptotic activity equal 
to wt-Survivin but expressed at higher levels in hematopoietic stem cells (unpublished 
data).   
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Altieri, D.C., 2008 [10] 
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Figure 1.  Wild-Type Survivin Protein Structure and Protein-Protein Interaction 
Sites.  Schematic representation of the wild-type Survivin protein showing its known 
function domains, baculovirus IAP repeat (BIR), nuclear export signal (NES) and alpha-
helices, as well as binding partners and their binding sites (arrows): INCENP, Borealin, 
SMAC, X-linked IAP (IAP), heat shock protein 90 (Hsp90) and Aurora Kinase B.  
Phosphorylated residues (arrow followed by residue) indicate phosphorylation sites by 
known kinases: Cdk1 (also known as p34Cdc2) at Threonine-34, Aurora kinase B at 
Threonine-117 and Protein Kinase A at Serine-20.   
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Sampath, J. and Pelus, L.M., 2007[9] 
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Figure 2. Survivin Splice Variant Exon Structures.  The top diagram shows the order 
of the exons in the Survivin gene (boxes) from Exon I to Exon IV.  The bottom diagram 
represents the exons and designation of Survivin splice variants that have been reported 
and their mature protein verified: wt-Survivin, Survivin 2α, Survivin 2B, Survivin Ex3, 
Survivin 3B and Survivin 3γ; this excludes varients simply identified from EST database 
searches or RT-PCR.   
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There has been an ongoing effort to determine the role of the Survivin splice 
variants in cancer [30].  Early studies suggested that expression of the Survivin 2B 
variant may have a negative role on cancer progression and malignancy.  A high level of  
expression of Survivin 2B was associated with good prognosis in patients with 
neuroblastoma and lower expression is associated with malignant tissues [31].  Survivin 
2B expression is lower in later stages of renal cell carcinomas [32] and inversely 
proportional to tumor differentiation and invasion in gastric cancer [33] and dominant in 
some benign brain tumors [34].  The Survivin splice variant Ex3 has been reported to 
have the opposite effect to Survivin 2B and inversely proportional to apoptotic index 
[35].  High levels of Survivin Ex3 mRNA have been reported to correlate with high 
proliferative activity in hepatocellular carcinoma [36].  In patients with breast 
carcinomas, Survivin variants 2B, Ex3 and 3B have been detected, and while Survivin 
2B was detected at higher levels in small tumors, 3B was more frequent in high-grade 
carcinomas and was more frequent in tumors with p53 gene mutation [37].  Relatively 
little is known about variant Survivin 2-alpha (2α) in cancer, however recent studies have 
shown that there is no change in Survivin 2α expression between paracancerous and 
cancerous tissues in gastric cancer patients [38].  In contrast, Survivin 2α expression was 
elevated in therapy resistant breast carcinoma cells [39].  However, with the identification 
of 10 new splice variants in addition to those discussed above it is now clear that the 
primers and probes used to detect the Survivin splice variants evaluated for activity to 
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date are not sufficiently specific and will detect more than one variant.  As a 
consequence, previously reported correlations may be inaccurate. 
 Although the subcellular localization of wild-type Survivin affects its function in 
cells, how subcellular localization affects the function of individual Survivin splice 
variants is relatively unknown and is currently being investigated.  The Survivin 2B 
variant has been found to be expressed mainly in the cytosol and a small fraction in the  
mitochondria [26, 40].  This latter finding may be important because Survivin 2B, which 
can bind wt- Survivin, may prevent its release from the mitochondria and in turn prevent 
inhibition of caspase-9 mediated apoptosis [41, 42].  In contrast, the Ex3 Survivin 
variant appears to localize mainly to the nucleus [26] as well as to the nucleoli, where it is 
degraded [43], and only a small portion localizes to the mitochondria [40].  During 
mitosis, Survivin Ex3 appears to translocate to the mitotic spindles [42], however the 
effect of its subcellular localization and its function have yet to be elucidated.  Survivin 
2α appears to localize to both the nucleus and cytoplasm during interphase but remains in 
the cytoplasm during mitosis [44].  Little is known about the subcellular localization of 
the recently described Survivin 3B variant [45] or the 3G and 3G-variants discovered in 
our laboratory.  However, one study shows that Survivin 3B interacts with chromosomal 
passenger proteins and suggests that it has an active nuclear export signal (NES), possibly 
indicating both cytoplasmic and nuclear distribution [29]. 
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Role in Apoptosis 
Survivin is a member of a family of caspase-specific inhibitors.  It effectively 
inhibits the functions of caspases 3, 7 and 9, as well as the proapoptotic protein second 
mitochondria-derived activator of caspases/direct IAP binding protein with low pI 
(Smac/DIABLO) [46].  Caspase-9 is an initiator caspase and is activated in response to 
apoptotic stimuli derived from the instrinsic pathway of apoptosis, which is mediated via 
mitochondrial responses [47].  Mitochondria release cytochrome-c that recruits the 
apoptotic protease-activating factor-1 (Apaf-1), which in turn binds to, cleaves and 
activates caspase-9.  Together these proteins form what is known as the “Apoptosome” 
[47-50] (Figure 3).  The Apoptosome in turn leads to the cleavage of inactive procaspase-
3 into its active form, which is known as an effector caspase [51].  Caspase-3 has a 
plethora of cleavage targets, including the protein inhibitor of caspase-activated 
deoxyribonuclease (iCAD), which sequesters CAD and upon its release translocates to 
the nucleus and degrades DNA [52].  Survivin deficiency exacerbates apoptosis in 
response to mitochondria-mediated apoptosis, also known as the intrinsic apoptosis 
pathway [53].  Survivin also binds to the mitochondria-derived proapoptotic protein 
Smac/DIABLO that binds to IAPs and acts to counterbalance anti-apoptotic proteins [20].  
Studies have also shown that over-expression of Survivin protects cells against apoptosis 
induced through the extrinsic apoptotic pathway by agents that signal through death 
domain receptors such as Fas ligand (FasL) and tumor necrosis factor-alpha (TNF-α) [54, 
55].  Another binding partner for Survivin is CRM1, which is a nulear export receptor 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Oberst, A. et al., 2008 [51] 
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Figure 3.  The Apoptosome.  The diagram represents proteins upstream as well as 
downstream of cytochrome-c release from the mitochondria.  The Apoptosome 
progression is demonstrated here wherein proapoptotic internal stimuli activate 
proapoptotic factors such as Bad and BID in turn leading to the activation of proapoptotic 
Bax/Bak leading to mitochondrial outer membrane permeabilization (MOMP) and 
release of cytochrome-c.  Pro-apoptotic activation of Bax/Bak can be counter-acted by 
anti-apoptotic factors such as Bcl-2/Bcl-xL, but these too can be inhibited by Bad.  The 
released cytochrome-c binds the co-factor Apaf-1 and together they bind and activate 
procaspase-9 and form the functional Apoptosome.  The Apoptosome subsequently 
cleaves effector procaspases-3 and -7 into their active forms ultimately leading to 
apoptosis. 
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that interacts with NES domains in shuttled proteins, and is necessary for nuclear export 
of Survivin into the cytoplasm that in turn is necessary for its anti-apoptotic function [21, 
56, 57].   
Role in Cell Cycle 
It has been reported that in normal cells Survivin protein expression is up-
regulated during progression to G2/M phase of cell cycle and at anaphase Survivin is 
targeted for phosphorylation by the heterodimeric kinase p34Cdc2/Cyclin B1 at 
Threonine-34, an event considered to be important for both its cell cycle and anti-
apoptotic functions [18].  This is further supported by evidence that a Threonine 34-to-
Alanine non-phosphorylatable mutation produces a dominant-negative (dn) form of 
Survivin, which has a negative effect on cell cycle progression and apoptosis [58-62].  
Survivin activates the Cdk2/Cyclin E complex leading to an increase in pRb 
phosphorylation contributing to cell cycle progression, as well as associates with Cdk4 
leading to its nuclear translocation and accelerates cellular exit from S-phase and entry 
into G2-phase [63]. 
 During the transition between metaphase and anaphase, the chromosomal 
passenger complex (CPC) localizes to the microtubules at the central spindle.  This 
complex is comprised of Aurora kinase B, INCENP, Survivin and Borealin and is 
important for chromosomal condensation, spindle assembly, microtubule-kinetochore 
interaction and chromosomal alignment, as well as the spindle checkpoint and completion 
of cytokinesis [64-66].  Borealin, also known as Dasra, binds to Survivin and directs 
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Survivin binding to INCENP rather than to Aurora kinase B [67, 68].  In the absence of 
Survivin cells undergo mitotic catastrophe (a type of cellular death) and cycling cells 
cannot properly complete mitotis.  However, recently, Yang et al., reported that cells 
could in fact complete cell cycle in the absence of Survivin, however, they suffered a 
great number of cell division abnormalities including aberrant chromosome segregation 
and incomplete cytokinesis, highlighting the necessity of Survivin in order to maintain 
normal cell cycling [69].  Although caspases-2 and -3 have been implicated, it is still 
unclear whether or not caspase activation is necessary for mitotic catastrophe to occur 
[70-72].  A role for these caspases could prove important because their activities are 
inhibited by Survivin and would further implicate Survivin in this process.  
Role in Hematopoiesis 
Survivin is expressed in normal hematopoietic cells and our laboratory has shown 
that it plays a physiological role in hematopoietic stem and progenitor cell function [3, 
73, 74].  In hematopoietic cells, Survivin functions by regulating both cell cycle and 
caspase inhibition and is upregulated in response to hematopoietic cytokines such as 
thrombopoietin (Tpo), stem cell factor (SCF) and Flt3 ligand (FL), before entry into cell 
cycle [73].  Recently, a study in caspase-3 knockout mice showed dampened responses to 
specific cytokines and contribution to quiescence of hematopoietic stem cells [75], 
confirming that Survivin would act as a counter-balance, consistent with our laboratories 
finding that Survivin and active caspase-3 levels are found in inverse proportion in 
CD34+ human hematopoietic stem cells [3]. 
 14 
 
Target of Cancer Therapeutics 
 Survivin is found to be highly expressed in virtually all cancers with few 
exceptions [1, 76], and coupled with its limited expression in most adult tissues, has 
made Survivin an attractive cancer therapeutic target.  Our laboratory has shown that dn- 
(T34A)-Survivin can abrogate the effects of constitutively active-H-Ras [62].  Studies 
using either the dn-T34A-Survivin alone [77] or a dual T34A/D53A mutated Survivin 
have shown efficacy on down-regulation of the anti-apoptotic effect of wt-Survivin on 
aberrant cells [77, 78].  In addition, the use of the human immunodeficiency virus (HIV) 
Tat protein that allows passage through the cell membrane, fused with the T34A-Survivin 
has been found to have a negative effect on the growth and survival of breast cancer and 
melanoma cells [79, 80].  Another method of targeting Survivin is the use of an 
adenoviral vector for combinatorial therapy.  To this end, studies have shown that Adeno-
T34A therapy in combination with the administration of the microtubule-affecting drug 
paclitaxel sensitizes prostate cancer cells to chemotherapy [81].  Furthermore, Adeno-
T34A and Adeno-caspase-3 combinatorial treatment reduces Survivin expression in an 
ovarian carcinoma cell line [60]. 
It has been found that heat shock protein-90 (Hsp90) stabilizes Survivin, which 
means that disruption of Hsp90 activity in turn disrupts Survivin protein levels [12, 22].  
Currently, drugs that bind to the ATP-binding pocked within Hsp90 with higher affinity 
than Hsp90’s normal binding partners are being evaluated as therapeutic agents targeting 
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Survivin.  In addition, Geldanamycin and its deratives and AICAR are also being studied 
[82-87].   
Hematopoiesis 
Overview 
 Hematopoiesis is the lifelong process through which the cells of the blood and 
immune system are produced.  These cells have an array of different functions, ranging 
from delivering oxygen to the body’s tissues, preventing blood loss, to defending against 
pathogens.  Hematopoietic stem cells are defined as cells with the ability to not only give 
rise to all the lineages of the blood but to have self-renewal capacity (Figure 4) [88].  
Hematopoietic stem cells also produce multilineage progenitor cells that have the ability 
to give rise to cells in multiple but not all lineages and possess a limited self-renewal 
potential (such as the common myeloid progenitor cell or the common lymphoid  
progenitor cell), which in turn gives rise to more restricted progenitor cells that give rise 
to individual cell lineages and have no self-renewal potential [89]. 
Markers/Definitions 
Currently the standard definition of a hematopoietic stem cell in humans, whether 
it is derived from umbilical cord blood (UCB) or bone marrow, is a cell possessing the 
cluster designation (CD) 34 and 90 markers but lacking CD38 and 45RA, termed  
CD34+CD38-CD90+CD45RA-  cells [88, 90-93].  These cells can be isolated using 
fluorescence activated cell sorting (FACS) using fluorochrome-conjugated antibodies.  In 
mice, the definition of an HSC is a cell expressing Sca-1, c-Kit and SLAM (CD150)  
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Figure 4.  The Hierarchy of Hematopoeisis.  In the formation of the blood and its 
components, the hematopoietic stem cell first gives rise to multipotent progenitor cells as 
well as more stem cells (self renewal).  The multipotent progenitor cells in turn give rise 
to lineage restricted (oligopotent) progenitor cells such as the common lymphoid 
progenitor (CLP), common myeloid progenitor (CMP), granulocyte macrophage 
progenitor (GMP) and megakaryocytic/erythoroid progenior (MEP).  Through further 
differentiation and specialization, the oligopotent progenitor cells give rise to all the 
mature blood cell elements.  
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markers on their cell surface and lacking expression of CD48 and any markers defining 
lineage differentiation (Lin), e.g., T3, T4, T8, MAC1, Gr1, B220, Flk2 or CD34, or 
expressing Sca-1 and c-Kit and negative for CD34 and lineage markers.  These cells are 
termed  SLAM SKL or CD34- SKL cells and contain the long-term repopulating HSC at 
a frequency of ~1 in 3 [94]. 
P34Cdc2/CDK1 
 Cyclin dependent kinase 1 (CDK1) or p34 Cell Division Cycle 2 gene 
(p34Cdc2) is a 34 kilodalton member of the normal cell cycle machinery.  Cdc2  
heterodimerizes with the 55 kilodalton protein cyclin B1, and together they form what is 
known as the mitosis promoting factor (MPF).  MPF is activated at the end of G2 phase 
(dephosphorylated at Thr14/Tyr15) by the phosphatase Cdc25c causing it to translocate 
to the nucleus where it helps usher cells from G2 phase into Mitosis [95].  Figure 5 
provides a schematic of p34Cdc2’s activity in cell proliferation [96].  
Role in Cell Cycle 
 P34Cdc2/Cyclin B1 is upregulated in late G2 phase of the cell cycle and peaks at 
metaphase and is involved in centrosome separation, which is required for bipolar spindle 
assembly via phosphorylation of motor proteins [97].  It also targets lamina for 
phosphorylation aiding in nuclear structure destabilization that leads to a breakdown of 
the nuclear envelope [98].  P34Cdc2/Cyclin B1 also contributes to chromosome 
condensation through condensin phosphorylation [99] and is auto-regulated by helping to  
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Figure 5.  Cdc2 and Cell Cycle.  This figure summarizes the accepted role of Cdc2 in 
the cell cycle during normal mitosis.  During most of the cell cycle Cdc2 is kept in an 
inactive state by phosphorylation at its Threonine-34 and Tyrosine-15 residues by the 
kinases Wee1 and Myt1.  During progression from the G2 phase into mitosis, the 
phosphatase Cdc25c dephosphorylates these residues and cyclin activating kinase (CAK) 
phosphorylates Cdc2 Threonine-161 resulting in an active Cdc2 that binds Cyclin B1 to 
form a heterodimeric kinase.  Once active Cdc2/Cyclin B1 translocates to the nucleus 
where among other targets, it phosphorylates Survivin at Threonine-34 during anaphase.  
Afterward, Cyclin B1 is then targeted for degradation and Cdc2 is once again rendered 
inactive. 
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activate the anaphase promoting complex (APC) before cells enter anaphase, which in 
turn targets proteins for degradation including Cyclin B1 [100-103]. 
Role in Apoptosis 
 There is considerable evidence that improper activation of Cdc2 is involved in 
activation of apoptosis.  Active Cdc2 can cause aberrant entry into mitosis, which causes 
premature chromatin condensation and apoptosis [104-107] and inhibition of Cdc2 with a 
dominant-negative mutant can protect cells from apoptosis or mitotic catastrophe induced 
by Chk2 inhibition [70, 108].  However, studies with Cdc2 deficient cells showed that 
they could still undergo apoptosis, while other studies have shown that Cdc2 
activation/inactivation levels do not change when these cells undergo apoptosis.  
Although its exact role is still not completely understood, it is clear that Cdc2 does in fact 
have a role during certain instances of apoptosis, and likely in a cell-specific manner 
[109-111].  The current paradigm for Cdc2’s involvement in apoptosis are outlined in 
Figure 6. 
Cell Cycle 
Overview 
Cell Cycle is the process that cells undergo to divide and produce two genetically 
identical daughter cells.  It begins with a cell within a quiescent state G0- or in stasis G1-
Phase.  Upon receiving instrinsic or extrinsic mitogenic signals, the cell is activated and 
initiates its progression into S-Phase wherein the cell duplicates its genome, followed by 
the G2-Phase where the cell produces most of its protein repertoire (Figure 7a).  The G0 to  
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Figure 6 
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Figure 6.  Cdc2 and Apoptosis.  Improper activation of Cdc2 can lead to mitotic 
catastrophe.  In ErbB2-expressing cells, ErbB2 targets Cdc2 Tyrosine-15 for 
phosphorylation to help keep it properly inactive.  However, the use of the ErbB2-
inhibiting drug Herceptin or microtubule destabilizing drug Taxol result in improper 
Cdc2 activation and ultimately mitotic catastrophe. 
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Figure 7.  Cell Cycle.  A) Cell cycle overview.  Cell cycle is separation into four major 
phases: G1, S, G2 and M.  B) Mitosis overview.  M-phase can be divided into five sub-
phases: Prophase (formation of the mitotic spindles, chromatin condensation), 
Prometaphase, Metaphase (alignment of the chromosomes), Anaphase (attachment of the 
chromosomes to the mitotic spindles and separation) and Telophase (formation of the 
cleavage furrow) ultimately to cytokinesis, the formation of two daughter cells.  C) Cell 
cycle checkpoints.  Cells have cell cycle checkpoints in place to ensure faithful 
replication of cells and avoid aberrant growths.  If cells do not pass the cell cycle 
checkpoint their progression is halted or apoptosis can occur.  The first checkpoint exists 
between G1 phase and S phase to ensure the microenvironment is conducive for cell cycle 
progression.  The second checkpoint exists before entry into mitosis to ensure faithful 
DNA replication and again a conducive microenvironment for progression to occur.  
Lastly, before completion of mitosis, a checkpoint exists to ensure proper attachment of 
the mitotic spindles and chromosomes. 
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G2 phase of the cell cycle is known as Interphase.  Thereafter, cells enter their mitotic 
phase, which is divided into prophase, prometaphase, metaphase, anaphase and telophase 
(Figure 7b).  Following proper cytokinesis, two daughter cells are formed.  
Cell Cycle Arrest and Cell Cycle Checkpoints 
 In order for cell cycle to progress correctly, there are a number of checks and 
balances set in place in order to ensure proper division and replication; known as cell 
cycle checkpoints (Figure 7c).  The G1 checkpoint is set-up to ensure that cells are 
genomically stable and healthy before entering S-phase where DNA is replicated.  The 
“master regulator” of the G1 checkpoint is the p53 tumor suppressor protein [112].  The 
G2 checkpoint protects cells from potentially detrimental replication following DNA 
damage and is governed by the Chk1, Wee1 and Myt1 kinases [114].  It is at G2, after 
activation of Wee1, that the p34Cdc2/Cyclin MPF ushers cells into mitosis.  The spindle 
checkpoint in metaphase functions to ensure that the cells have properly aligned their 
chromosomes and that the machinery is adequately prepared to separate the 
chromosomes and complete cytokinesis, otherwise mitotic catastrophe occurs [115]. 
Apoptosis 
Overview 
 Apoptosis, or programmed cell death, is a cellular process that ensures that 
aberrant, unwanted or unnecessary cells are properly disposed of (e.g., cancer cells, 
excess T cells after clearance of infection and cells during embryonic development).  The 
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central executer of this process is the caspase cascade.  There are two pathways that 
activate the caspase cascade: the instrinc and extrinsic apoptotic pathways. 
Intrinsic Pathway 
 The intrinsic pathway of apoptosis is designed to sense internal signals derived 
from irreparable damage caused within the cell.  Components of the instrinsic apoptotic 
pathway include Smac/DIABLO, Bad, Apaf-1, cytochrome-c, caspase-9, caspase-3 and 
proapoptotic bcl-2 family members [116].  Internal signals generated by DNA damage, 
cytotoxic drugs or improper cell cycle, compromise mitochondrial membrane potential 
resulting in release of proapoptotic factors such as cytochrome-c and Smac/DIABLO.  
Cytochrome-c binds to Apaf-1, which in turn binds with and activates caspase-9 forming 
the Apoptosome that with the co-factor dATP results in the activation of effector 
caspases-3 and -7 and ultimately cell death (Figure 8).   
Extrinsic Pathway 
 The extrinsic pathway of apoptosis is designed to sense external signals from the 
microenvironment that can indicate that a cell’s viability is no longer necessary.  
Components of the extrinsic apoptotic pathway are mostly ligands and receptors of the 
TNF superfamily of receptors that possess death domains in their intracellular portion.  
For TNF receptors, these are termed tumor necrosis factor receptor-associated death 
domains (TRADD) and for Fas receptor, they are termed fas receptor-associated death 
domains (FADD).  In the extrinsic pathway, external factors such as TNF-related 
apoptosis inducing ligand (TRAIL), Fas ligand or high levels of tumor necrosis factor-α  
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Figure 8.  Instrinsic and Extrinsic Apoptotic Pathways of Apoptosis.  A) Extrinsic 
apoptosis occurs when external signals (such as Fas ligand on the surface of a killer 
lymphocyte) bind to Fas receptors on another cell leading to their aggregation, activation 
and formation of the death inducing signaling cascade (DISC), which itself activates the 
caspase cascade leading to apoptosis.  B) Intrinsic apoptosis occurs when signals within 
the cell indicate that an uncorrectable aberration has occurred (such as irreparable DNA 
damage), leading to compromising of the mitochondrial membrane potential releasing 
cytochrome-c and leading to formation of the Apoptosome, activation of the caspase 
cascade and ultimately apoptosis.   
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result in aggregation of tyrosine kinase receptors of the TNF Superfamily of receptors 
such as FasR [116].  Subsequently their intracellular death domains bind, along with 
procaspase-8, to form the Death Inducing Signaling Complex (DISC).  DISC is 
responsible for the cleavage of initiating procaspase 8 into its active form and in turn 
caspase-8 activates the effector caspases-3 and -7 (Figure 8). 
Caspases-3, -7 and -9 
 Cell death (CED) proteins are the central machinery of apoptosis that were first 
discovered in C. elegans [117, 118].  The mammalian homologs have been identified [49, 
119-121] and include the cysteinyl aspartate proteinases or caspase family.  Caspases can 
be categorized into two groups: initiator caspases and effector caspases [122].   
Initiator caspases have longer prodomains (compared to effector caspases) as well as 
caspase recruitment domains (CARD) or death effector domains (DED) (Figure 9) and 
function by interacting with upstream signaling proteins.  Caspase-9 forms part of the 
apoptosome and interacts with Apaf-1 through CARD-CARD domain interactions [123].  
Caspase-9 is also a substrate of both Akt and Erk (extracellular signal regulated 
kinase)/MAPK (mitogen activated protein kinase), which phosphorylate caspase-9 at 
Serine-196 and Threonine-125, respectively [124, 125] and inhibit its proapoptotic 
activity.  During mitosis, the Cdk1/Cyclin B1 complex can also phosphorylate caspase-9 
at Threonine-125 and inhibit its activity [126].  
 Effector caspases are categorized by short prodomains and are normally cleaved 
by initiator caspases.  They also exist as homodimers in their procaspase form.  Caspases  
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Adapted from Li, J. and Yuan, J., 2008 [122] 
 32 
 
Figure 9.  Caspase Structures and Domains.  This figure shows the domains present in 
the caspase family of proteinases such as the p10 and p20 subunits.  L1-L4 represent the 
catalytic center loops.  CARD (caspase recruitment domain) domains are necessary for 
protein-protein interaction with other CARD-containing proteins, and DED (death 
effector domain) domains are required for interaction with upstream signaling 
components of the apoptotic pathway. 
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3 and 7 are effector caspases.  They are quintessential in executing apoptosis, which is 
illustrated in caspase-3/caspase-7 double-knockout mice that not only show a marked 
apoptotic defiency, immediate postbirth mortality and exencephaly, but their derived 
mouse embryo fibroblasts (MEF) also exhibit strong resistance to both intrinsic and 
extrinsic apoptosis [127]. 
Wee1 Kinase 
Structure, Function and Role in Cell Cycle 
 Wee1 is a member of the Wee1 family of kinases that includes Myt1 and Wee1 
that help to coordinate the cell cycle machinery.  Its main known function is the 
inactivation of the Cdc2/Cyclin B1 complex during mitosis by phosphorylation of Cdc2  
on Tyrosine-15.  Wee1 is approximately 90 kiloDaltons in size and together with Chk1 
and Myt1 regulates the G2 checkpoint [114].  It also regulates Cdc2 activity through 
subcellular localization, i.e., the two cannot both exist in their active states within the 
same subcellular compartment [128].  It has been shown that lack of Wee1 kinase results 
in early entry into mitosis before the deficient cells have had sufficient time to grow, 
resulting in smaller daughter cells [129]. 
Role in Apoptosis 
 Over-expression of Wee1 in umbilical cord blood (UCB) CD34+ hematopoietic 
cells has been reported to provide a protective effect from cytotoxic chemotherapeutic 
agents [130].  Similarly, ectopic Wee1 protects BHK cells from apoptosis induced with 
granzyme B [131].  Conversely, down-regulation of Wee1 by RNA interference 
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sensitized HeLa cells to apoptosis [114] and was seen to have a similar effect in HIV-1 
VPR-induced apoptosis [132], underlining its cytoprotective role.  Interestingly, it has 
been suggested that cytoplasmic localization of Wee1 is required to promote survival, 
whereas nuclear localization promotes apoptosis [133].  
Purpose of This Study 
The role of Survivin in hematopoiesis is a focus of our laboratory.  We have 
shown that Survivin has a role in regulating hematopoietic stem cell maintenance and 
survival and is required for hematopoietic stem and progenitor cell (HSPC) cell cycle 
entry [3, 73, 134].  It is becoming clear that Survivin’s antiapoptotic function is 
conducted mainly through its inhibition of proapoptotic proteins such as Smac/DIABLO 
and caspases-3, -7 and -9.  Over-expression of Survivin results in increased p34Cdc2 
phospho-Tyrosine-15 levels.  While it is known that p34Cdc2/Cyclin B1 targets Survivin 
for phosphorylation, Survivin does not contain instrinsic kinase activity thus the 
mechanism by which Survivin over-expression results in an increase in p34Cdc2-
Tyrosine-15 phosphorylation is unclear.  Understanding the role of Survivin has 
significant implications on the biology of stem cells and cancer biology overall.  The 
focus of this work was to elucidate the mechanism of action through which Survivin 
regulates p34Cdc2.  Using the BaF3 mouse hematopoietic cell model we have identified 
that Survivin protects the Wee1 kinase from caspase-3 dependent degradation that in turn 
maintains inactivating Cdc2  phospho-Tyrosine-15 levels, resulting in a block in 
apoptosis and enhanced overall cell survival and proliferation.   
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MATERIALS AND METHODS 
Cell lines 
The IL-3 dependent murine BaF3 cell line was used as a model for normal growth 
factor-dependent hematopoietic cells.  BaF3 cells were cultured in RPMI-1640 (Lonza 
Inc., Allendale, NJ) supplemented with 10% heat-inactivated fetal bovine serum (HI-
FBS) (HyClone Sterile Systems, Logan, UT) and 100 pg/mL of recombinant murine IL-3 
as well as 100 units/mL of Penicillin/Streptomycin (Lonza Inc.) in T75 tissue culture 
flasks.  BaF3 cells were permanently transduced with wild-type (wt) or dominant-
negative (dn) Threonine-34-to-Alanine mutation (T34A) mouse Survivin constructs in 
the bicistronic MIEG3(-) eGFP containing vector as previously described [61].  GFP 
positive cells were FACS-sorted gating on the highest luminescence-emitting cells (high 
eGFP expression correlates directly with Survivin expression) and transduced cells 
maintained as cell lines.  The wt- and ITD-Flt3 BaF3 cell lines were provided by Dr. DG 
Gilliland, Harvard Medical School, Boston, MA.  The ITD-Flt3 BaF3 cells were 
maintained in culture using the same conditions described above. 
 The human MCF-7 breast cancer epithelial cell line was cultured in αMEM media 
supplemented with 10% HI-FBS, 100 units/mL of Penicillin/Streptomycin and 2.5 mL of 
L-Glutamine per 500 mL of media in 10 cm tissue culture dishes.  These cells lack 
caspase-3 protein due to a 47-bp deletion in the corresponding gene [135].  Human  
Jurkat T-cells were cultured in RPMI-1640 media supplemented with 10% HI-FBS and 
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0.1% sterile 2-Mercaptoethanol (Bio-Rad Laboratories, Hercules, CA) in T75 tissue 
culture flasks. 
Transductions 
 Briefly, for retroviral transductions, purifed MIEG-IRES-EGFP plasmid alone or 
containting wt-Survivin or dn-Survivin were transfected into Phoenix Eco cells using 
Lipofectamine 2000 (Invitrogen, Carslbad, CA).  After sequential infection of normal 
BaF3 cells, GFP+ (infected) cells were sorted and isolated by FACS and cultured using 
the conditions described above for BaF3 cells. 
Antibodies and Reagents 
The caspase inhibitors Ac-DEVD-CHO, Ac-LEHD-CHO and Z-VAD-FMK and 
the Hsp90 inhibitor AICAR were purchased from BioMol International (Plymouth 
Meeting, PA).  The anti-Wee1, anti-p34Cdc2 and anti-Actin antibodies were purchased 
from Santa Cruz Biotechnology (La Jolla, CA).  Anti-p34Cdc2 phospho-Tyrosine-15, 
anti-p34Cdc2 and anti-PARP antibodies were from Cell Signaling (Boston, MA).  Anti-
Survivin antibody (Clone AF886) was from R&D Systems (Minneapolis, MN).  
Annexin-V-PE and 7-AAD were purchased from BD Pharmingen (San Jose, CA) .   
Cell Lysis and Immunoblotting 
Cell lysates were prepared using, Triton-X lysis buffer (50 mM HEPES, pH 7.0, 
150 mM NaCl, 10% Glycerol, 1.2% Triton X-100, 1 mM EGTA, 1 mM EDTA, 10 mM 
sodium pyrophosphate, 100 mM NaF, 1mM phenylmethylsulfonyl fluoride, 1 mM 
sodium orthovanadate) or Urea-SDS lysis buffer (62.5 mM Tris (pH 6.8), 6 M urea, 10% 
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glycerol, 2% SDS, 0.003% bromophenol blue, and 5% 2-mercaptoethanol) [136], 
supplemented with Complete Mini protease inhibitor cocktail (Roche Diagnostics Inc., 
Indianapolis, IN).  The protein content in cell lysates was determined using a Bradford 
assay (Bio-Rad Laboratories).  Lysates were heated at 100 °C for 5 minutes then run on 
8% or 15% SDS-PAGE gels and transferred to PVDF membranes (Millipore, Billerica, 
MA) at 110 milliamps for 2 hours.  The membranes were blocked with 5% milk solution 
for 1 hour then probed for various proteins.  Stripping and reprobing was performed 
using RestoreTM western blot stripping reagent (Pierce Biotechnology, Rockford, IL).  
Measurement of western blot OD readings were performed using Adobe Photoshop.  
Individual blots were quantitated using the histogram application to obtain mean values.  
Experimental means were standardized to loading controls and final values were 
standardized to either vector or 0 hours which were given the value of 1.   
Immunoprecipitation 
Human Jurkat cells were harvested in log-phase growth and total cell lysates 
prepared as described above.  Two and one-half mg of lysate for each of three 
immunoprecipitations, normal rabbit IgG, Survivin and Wee1, were pre-cleared using 20 
uL per sample of protein agarose A/G beads (Santa Cruz Biotechnology) for 15 minutes 
with rocking at 4 °C and pre-cleared lysates transferred to new tubes containing 2.5 ug of 
the same antibodies used for immunoprecipitation.  Lysates were incubated for one hour 
and 50 uL of protein agarose A/G beads added to each sample and incubated overnight 
with rocking at 4 °C.  Immunoprecipitates were subsequently washed three times using 
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Triton-X lysis buffer and 35 uL of SDS-PAGE loading buffer added to 
immunoprecipitated samples.  SDS-PAGE loading buffer (6X) was added to 100 
microgram samples of total cell lysates.  Immunoprecipitates and total cell lysates were 
heated at 100 °C for 5 minutes and run on SDS-PAGE gels. 
Treatments 
Log-phase growing BaF3 cells were counted, washed and resuspended in serum-
free RPMI-1640 and plated in 6-well tissue culture plates at a concentration of 1x106 
cells per mL in 4 mL of media two-hours prior to treatment.  Caspase inhibitors were 
prepared as 1000X stock solutions in DMSO (Ac-DEVD-CHO and Ac-LEHD-CHO at 
25 mM and Z-VAD-FMK at 20 mM).  Control groups received DMSO alone.  Cells were 
treated for 2 hours at 37 °C, harvested and lysates prepared.  For analysis of the effects of 
Hsp90 inhibition, AICAR was prepared in DMSO and used at 25 uM.  Cells receiving 
AICAR or DMSO were harvested at various time points, lysates prepared using Triton-X 
lysis buffer and samples run on SDS-PAGE.  In order to measure apoptosis, BaF3 cells 
were either plated at 1x105 cells/mL in 4 mL of normal growth media or RPMI with 1% 
FBS without IL-3 for 0, 24 or 48 hours, cell pellets collected and apoptosis quantitated 
using Annexin V/7AAD and flow cytometry.  Adherent MCF7 cells were treated with 
caspase inhibitors in similar fashion to BaF3 cells.  MCF7 cells were trypsinized 
(Trypsin, Lonza) for 5 minutes, washed, counted and plated at 2.5 x 105 cells per mL in 
10 mL of media in 10 cm tissue culture plates for 24 hours prior to treatment to allow 
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readherence to the plate.  At 24 hours post-plating, cells were treated and then harvested 
and lysates prepared. 
Flow Cytometry 
In order to quantitate apoptosis, cells were washed and resuspended in Annexin-V 
binding buffer and Annexin-V and 7-AAD (BD Pharmingen) added to individual 
samples.  Annexin-V single-positive, 7-AAD single-positive, Annexin-V/7-AAD double-
positive as well as double-negative populations were quantitated in triplicate samples by 
FACS using BD software CellQuest. 
Statistics 
GraphPad t-test calculator, available online at  
http://www.graphpad.com/quickcalcs/ttest1.cfm was used to perform statistical analyses.  
Individual readings were entered into the calculator and mean and SEM values obtained, 
statistical signifance was determined as a p value less than 0.05. 
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RESULTS 
Chapter 1 
 Survivin Maintains Phosphorylation of p34Cdc2 at Tyrosine-15 
Over-Expression of Survivin Correlates with Survival and Elevated Phospho-Tyr15-Cdc2 
Levels 
 Growth factor withdrawal induces apoptosis of BaF3 cells over 48 hours post-
withdrawal measured by Annexin V and 7AAD staining (Figure 10).  Ectopic expression 
of wt-Survivin protected cells from apoptosis at 24 and 48 hours.  In contrast, in cells 
over-expressing the dominant-negative (dn) T34A-Survivin, increased apoptosis was 
observed.  In addition, viable cell counts performed using trypan blue exclusion 
demonstrated that wt-Survivin over-expression increased the total number of viable cells 
compared to MIEG and T34A-Survivin-transduced cells (Figure 11).  As an additional 
measurement of apoptosis, we quantitated intracellular caspase-3 activity by intracellular 
flow cytometry.  Using anti-active (cleaved) caspase-3 antibody we observed a higher 
level of caspase-3 activity in MIEG and T34A-transduced BaF3 cells than in cells over-
expressing wt-Survivin (Figure 12), consistent with Survivin’s ability to abrogate 
caspase-3 activity [54].   
An additional and interesting observation was made when these cells were 
analyzed further using western blots.  Cells expressing ectopic wt-Survivin contained 
significantly higher levels of Tyrosine-15 phosphorylated p34Cdc2 (an inhibitory  
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Figure 10 
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Figure 10.  Early Apoptotic Index of the BaF3-Transduced Cell Lines.  MIEG, wt-
Survivin and dn-T34A-Survivin transduced BaF3 cells were washed, counted and 
2.5x105  cultured in RPMI media with 1% HI-FBS without IL-3 for 24 or 48 hrs in 
triplicate in 6-well tissue culture plates.  At 24 and 48 hours after culture intitation, cells 
were harvest, washed and stained with Annexin-V and 7AAD (as described in materials 
and methods) and apoptosis quantitated by FACS analysis.  Data is expressed as mean % 
Annexin V+ 7AAD- cells ± S.E.M. for n=3 experiments, p = <0.05 
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Figure 11 
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Figure 11.  Viable Cell Counts of the BaF3 Cell Lines.  MIEG, wt-Survivin and dn-
T34A-Survivin transduced BaF3 cells were washed, counted and 2.5x105 cells cultured in 
pro-apoptotic media (cytokine-deficient, 1% HI-FBS) for 24 and 48 hours in triplicate in 
6-well tissue culture plates.  The total viable BaF3 cell number was quantitated 
microscopically at 24 and 48 hours of culture based on trypan blue dye exclusion.  Data 
are expressed as mean ± SEM from 3 experiments, p = <0.05   
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Figure 12 
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Figure 12.  Active Caspase-3 Assay.  MIEG and wt-Survivin transduced BaF3 cells 
were washed, counted and 2.5x105 cells cultured in 1% FBS/No-IL3 RPMI media for 24 
hours in triplicate in 6-well tissue culture plates.  Cells were fixed with 1% 
paraformaldehyde solution, their membranes permeabilized with 0.25% Triton-X/0.5% 
bovine serum albumin/phosphate-buffered saline and intracellular staining performed 
with anti-active caspase-3 (p17) antibody, then apoptosis quantitated by FACS analysis 
of p17 expression.  Blot is representative of 2 experiments and expressed as mean ± 
SEM.   
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Figure 13 
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Figure 13.  Protein Profile of the BaF3 Cells Lines.  Immunoblotting analysis was 
performed for phospho-Tyrosine15 p34Cdc2, Survivin and Actin on lysates from 
exponentially growing BaF3 cells transduced with either MIEG vector or wt-Survivin.  
One hundred micrograms of total cell lysates were run on 8-15% gradient SDS-PAGE 
gels.  Relative protein concentration relative to loading control is shown below bands.  
Blot is representitative of 3 experiments. 
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phosphorylation) compared to MIEG and T34A-transduced cells (Figure 13).  We have 
consistently seen that BaF3 cells expressing ectopic wt-Survivin have ~2-fold higher 
levels of Tyrosine-15 phosphorylated p34Cdc2, consistent with reports by others that 
indicate that Cdc2 activation is required for apoptosis [131, 137-140] and that Survivin 
decreases apoptosis.  In BaF3 cells in which Survivin is disrupted by expression of  dn-
T34A-Survivin, phospho-Tyrosine15 Cdc2 levels are ~4-fold lower than in cells 
expressing ectopic wt-Survivin.   
In order to study the effect of Survivin upregulation on Tyrosine-15 Cdc2 
phosphorylation in the context of acute leukemia [141], we utilized BaF3 cells that were 
permanently transduced with either wild-type (wt) Flt3 or internal tandem duplication 
(ITD) mutants of the Flt3 receptor derived from patients with acute myeloid leukemia 
(AML) [142].  In ITD-Flt3 BaF3 cells Survivin up-regulation is derived from the 
mitogenic signals induced by the constitutively active mutant Flt3 receptors, not from the 
introduction of ectopic Survivin and provides a model in which Survivin is up-regulated 
in a manner similar to primary cancers in vivo.  In these cells we observed significant 
upregulation of Survivin and elevated Cdc2-Tyr15 phosphorylation levels (Figure 14).  
Although at first glance phospho-Tyr15-Cdc2 levels appear lower in BaF3 cells 
expressing the N51 mutant, standardization to total Cdc2 (using densitometry) indicates 
that there is also a decrease in total Cdc2.  Therefore the levels of Cdc2-Tyr15 
phosphorylation levels are comparatively higher than wt-control.  This effect is further 
accentuated in cells that have been placed in proapoptotic conditions (cytokine-deficient,  
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Figure 14.  Cdc2-Tyr15 Phosphorylation is Elevated in BaF3 Cells Expressing ITD-
Flt3 Mutants.  BaF3 cells transduced with either wt-Flt3 or ITD-Flt3 mutations 51 or 78 
were harvested, lysates prepared, 100 ug of each sample run on SDS-PAGE gels and 
analyzed via immunoblotting for Cdc2-Tyr15 phosphorylation (pY15 Cdc2), total Cdc2, 
Survin and Actin.  Blots were quantitated using densitometric analysis, standardizing to 
wt-control (1.0), phospho-Cdc2 was standardized to total Cdc2, and Survivin to β-actin. 
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Figure 15 
A. 
 
B. 
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Figure 15.  ITD-Flt3 BaF3 Cells Show Increased Cdc2-Tyr15 Phosphorylation and 
Cell Survival.  A) Exponentially growing BaF3 cells transduced with wt-Flt3 or ITD-
Flt3 N51 and N78 mutants were washed with PBS, counted and 2.5x105 cells were 
cultured in triplicate in 6-well tissue culture plates for 24 hours in RPMI media 
containing 10% HI-FBS and 100 pg/mL IL-3 “24h Exp Gr” or 24 and 48 hours in 1% 
FBS/IL-3-depleted RPMI media to induce apoptosis.  Cells were harvested, lysates 
prepared and 100 ug of each sample run on SDS-PAGE gels and immublot analysis 
performed for phosphoTyrosine-15 Cdc2, total Cdc2 and Survivin.  B) Exponentially 
growing BaF3 cells transduced with wt-Flt3 or ITD-Flt3 N51 and N78 mutants were 
washed with PBS, counted and 2.5x105 cells were cultured in triplicate in 6-well tissue 
culture plates for 24 hours in RPMI media containing 10% HI-FBS and 100 pg/mL IL-3 
or 24 and 48 hours in RPMI media containing 1% HI-FBS and no IL-3.  Cell viability 
was quantitated usiung trypan blue exclusion.  Data are expressed as mean ± SEM and 
are representative of 3 experiments. 
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1% HI-FBS media) over 24 or 48 hours (Figure 15A).  We observe a marked increase in 
phospho-Tyr15-Cdc2 levels and Survivin in the 2 ITD-Flt3 mutants as compared to cells 
transduced with wt-Flt3. The BaF3 cells transduced with ITD-Flt3 mutants have a higher 
level of viability compared to cells transduced with wt-Flt3 as measured by total viable 
cell counts (Figure 15B).  The increased viability correlates with the increased phospho-
Tyr15-Cdc2 and Survivin levels observed, strongly suggesting the contribution of both in 
evasion of apoptosis.     
Phospho-Tyr15-Cdc2 Levels Are Not Due to An Increase in S-Phase 
 It is possible that the observed increase in phospho-Tyr15-Cdc2 levels in wt-
Survivin transduced cells could be due to an increase in the number of cells in S or G2-
phase, since p34Cdc2 is reported to be required for progression from G2 into Mitosis and 
is activated (dephosphorylated by Cdc25c).  Exponentially growing control and wt-
Survivin transduced cells were stained with propidium iodide and cell cycle stage 
analyzed using flow cytometry.  No significant difference in the proportion of cells in the 
S and G2/M phases was observed in these cells (Figure 16).  It is difficult to separate G2 
from M phase in BaF3 cells therefore the two are expressed together.   
Wt-Survivin Does Not Directly Interact with Wee1 Kinase 
 To further investigate the mechanism whereby Survivin up-regulates phospho-
Tyrosine-15 p34Cdc2 levels, we tested whether there was a direct binding between 
Survivin and Wee1.  We hypothesized that a physical interaction between Survivin and 
Wee1 would allow Survivin to act as a scaffold between Wee1 and p34Cdc2 and thereby  
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Figure 16.  Cell Cycle Analysis.  The graph shows the percentage of viable, 
exponentially growing MIEG or wt-Survivin transduced BaF3 cells in the various stages 
of cell cycle.  Exponentially growing cells were harvested, washed with PBS, counted 
and 1x106 cells fixed with 1% paraformaldehyde, permeabilized and stained with 
propidium iodide then analyzed by flow cytometry to determine the various stages of cell 
cycle within the .  N=3, no significant difference exists betweent the groups.  The 
percentage of cells in each stage of the cell cycle is expressed as Mean ± SEM. 
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enhance phospho-Tyr15-Cdc2 levels.  Using lysates from MIEG, wt- and dn-T34A-
Survivin transduced BaF3 cells, we performed immunoprecipitation of both Survivin and 
Wee1 proteins using 2.5 mg of whole cell lysates pre-cleared with A/G agarose beads.  
The immunoprecipitates and whole cell lysate controls were run on SDS- PAGE and 
immunoblotted for Survivin and Wee1 kinase.  Although Wee1 and  Survivin 
could be independently immunoprecipitated and detected, no co-immunoprecipitation 
was observed (Figure 17a).  Since the results could be due to antibody-mediated 
inhibition of association between these two proteins or a result of human Survivin not 
interacting with endogenous murine Wee1, we repeated the experiments using human 
Jurkat T-cells, which express high endogenous levels of both Wee1 and Survivin.  
Similar to BaF3 cells we observed independent immunoprecipitation and detection of 
Survivin and Wee1 but no direct binding between Wee1 and Survivin (Figure 17b). 
Wt-Survivin Increases Wee1 Kinase Protein Levels 
Since the Wee1 kinase can phosphorylate Cdc2 on Tyrosine-15, we probed 
lysates from BaF3 cells over-expressing wt-Survivin or dn-T34A-Survivin for Wee1.  
Cells over-expressing Survivin showed 2-fold higher levels of Wee1 protein compared to 
control MIEG and dn-T34A-Survivin transduced cells, the latter showing almost no 
detectable levels of Wee1 protein expression (Figure 18).  These results suggested that 
Survivin increases Cdc2-Tyr15 phosphorylation levels by increasing total levels of Wee1 
kinase. 
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Figure 17 
A. 
B. 
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Figure 17.  Immunoprecipitation of Survivin and Wee1 from human Jurkat T Cells.  
A) Exponentially growing MIEG-, wt-Survivin and dn-T34A-Survivin transduced BaF3 
cells were harvested, lysates prepared and 2.5 mg of total cell lysate used for each 
immunoprecipitation of Survivin (S) and Wee1 kinase (W).  Normal non-specific rabbit 
IgG (rIgG) was used as a control immunoprecipitation and 100 ug of total cell lysate 
from each sample were used as control.  After samples were run on 8-15% gradient SDS-
PAGE gels, immunoblotting was performed using anti-Survivin and anti-Wee1 
antibodies.  B) Exponentially growing Jurkat T-cells were harvested, lysates prepared and 
1 mg of total cell lysate used for control non-specific rabbit IgG immunoprecipitation 
(IgG) as well as immunoprecipitation of Survivin and Wee1 kinase.  One hundred 
micrograms of total cell lysate was run along side as a control on SDS-PAGE gels.  
Immunoblot analysis was performed using anti- Survivin and anti-Wee1 antibodies. 
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Figure 18 
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Figure 18.  Wee1 Kinase is Elevated in wt-Survivin Over-Expressing Cells.  Western 
blot analysis for Wee1 kinase, phospho-Tyrosine15 p34Cdc2, Survivin and β-Actin.  
Exponentially growing BaF3 cells over-expressing MIEG vector, wt-Survivin or dn-
T34A-Survivin were harvested, lysates prepared and 100 ug of each run on SDS-PAGE 
gel.  Immunoblotting analysis was performed followed by densitometric analysis of the 
bands, all standardized first to β-Actin then again standardized to MIEG control (MIEG = 
1.0).  Relative standardization is shown below the bands.  Data are representative of 5 
experiments. 
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Chapter 2 
Survivin Protects Wee1 Kinase 
Survivin Over-Expression is Sufficient to Maintain phospho-Tyr15-Cdc2 and Wee1 
Protein Levels 
We have shown that Survivin maintains Tyrosine-15 phosphorylation of 
p34Cdc2, which is associated with higher levels of Wee1 protein (Figure 18).  Since 
Wee1 is a target of caspase-3 [143, 144] and Survivin inhibits caspase-3 [54], we 
evaluated whether elevated Wee1 protein detected in cells ectopically expressing wt-
Survivin was a result of Survivin protecting Wee1 from degradation by caspase-3.  We 
first performed a dose response curve using the specific caspase-3 inhibitor, Ac-DEVD-
CHO, for 2 hours post a 2 hour incubation in serum-free media (Figure 19) and observed 
that there was not only an increase in phospho-Tyr15-Cdc2 levels but also an increase in 
the caspase-3 target whole Poly (ADP-Ribose) Polymerase (PARP), levels of which are a 
coincident measure of the inhibition of caspase-3 activity.  Peak elevation of phospho-
Tyr15-Cdc2 was observed at 25 and 50 uM.  We next compared MIEG and wt-Survivin-
transduced BaF3 cells treated for 2 hours with DMSO vehicle control or 50 uM of Ac-
DEVD-CHO after a 2 hour incubation in serum-free media, and analyzed the harvested 
cell lysates by immunoblotting.  The levels of phospho-Tyr15-Cdc2 were increased (4-
fold) in MIEG-transduced cells in the presence of the caspase-3 inhibitor however the 
levels of phospho-Tyr15-Cdc2 were unaffected by pharmacological caspase inhibition in  
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Figure 19 
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Figure 19.  Ac-DEVD-CHO Concentration Curve Correlates with Increased 
Phospho-Tyr15-Cdc2.  Exponentially growing MIEG-transduced BaF3 cells were 
washed with PBS, counted and 2.5 x 106 cells per well placed in serum-free RPMI media 
in 6-well tissue culture plates for two hours.  Cells were then treated with vehicle control 
DMSO or a specific caspase-3 inhibitor Ac-DEVD-CHO at increasing concentrations of 
1, 5, 10 and 25 uM for 2 hours.  Cells were subsequently harvested, lysates prepared and 
100 ug of each sample run on SDS-PAGE for immunblotting analysis of PARP, phospho-
Tyrosine15-Cdc2 and β-actin levels.   
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Figure 20 
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Figure 20.  Survivin Over-Expression is Sufficient to Maintain Phospho-Tyr15-Cdc2 
Levels.  Exponentially growing MIEG control and wt-Survivin transduced BaF3 cells 
were harvested, washed with PBS, counted and 2.5x106 cells per well placed in serum-
free RPMI media in 6-well tissue cultures plates.  Cells were treated with 50 uM of the 
caspase-3 inhibitor Ac-DEVD-CHO or DMSO control for 2 hours.  Cells were harvested, 
lysates prepared and 100 ug of each sample run on SDS-PAGE for immunoblotting 
analysis of phospho-Tyrosine-15 Cdc2 (pTyr15-Cdc2), PARP and β-Actin.   
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wt-Survivin over-expressing cells (Figure 20).  Reduction in the levels of cleaved PARP 
verified that the Ac-DEVD-CHO effectively reduced caspase-3 activity.   
In order to determine if increased Tyr15 phosphorylation of Cdc2 was due solely 
to inhibition of caspase-3, additional studies were performed using the selective Caspase-
7 inhibitor Ac-LEHD-CHO and the pan-caspase inhibitor Z-VAD-FMK.  In control 
MIEG-transduced cells, all three inhibitors increased the levels of phospho-Tyr15-Cdc2 
with no effect on total Cdc2 (Figure 21).  The highest levels of phospho-Tyr15-Cdc2 
were seen in cells treated with the pan-caspase inhibitor Z-Vad- FMK.  In cells over-
expressing Survivin, ectopic Survivin was sufficient to maintain elevated phospho-Tyr15- 
Cdc2 levels, which could not be increased further in the presence of these 
pharmacological caspase inhibitors.  Whole PARP levels increased primarily in the Ac-
DEVD-CHO treated cells.  The levels of Wee1 were generally higher in wt-Survivin 
over-expressing cells than in the MIEG-transduced cells except when vector cells were 
treated with the pan-caspase inhibitor Z-Vad-FMK.  Though varying slightly, all Wee1 
protein levels stayed at or above 2-fold over control-treated levels.  The effect of caspase-
7 inhibition on Wee1 and phospho-Tyr15-Cdc2 levels suggests that perhaps other 
caspases may be involved in this process.   
Caspase-3 is Required to Cause A Change to Wee1 Levels 
In order to further define a specific requirement for caspase-3 inhibition in the 
increased phospho-Tyr15-Cdc2 and Wee1 protein levels seen in wt-Survivin-transduced 
BaF3 cells, we performed similar studies in MCF7 breast cancer cells, which lack  
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Figure 21 
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Figure 21.  Pharmacological Inhibition with other Caspase Inhibitors.  Exponentially 
growing MIEG and wt-Survivin transduced BaF3 cells were harvested, counted, washed 
with PBS and plated at 2.5x106 cells per well in 6-well tissue culture plates in serum-free 
RPMI media for 2 hours.  Cells were then treated with either Ac-DEVD-CHO (DC) 
(25uM), Ac-LEHD-CHO (LC) (25uM) or Z-VAD-FMK (ZV) (20uM) or DMSO vehicle 
control for 2 hours.  Cells were harvested, lysates prepared and 100 ug of each sample 
run on SDS-PAGE for immunoblotting analysis of phospho-Tyr15-Cdc2, total p34Cdc2, 
PARP, Wee1 kinase and β-Actin.  Densitometric analysis comparing phospho-Tyr15-
Cdc2 to total Cdc2 levels and Wee1 to β-Actin levles are shown under the respective 
blots, standardizing to MIEG vehicle control = 1.0.  Data are representative of 2 
independent experiments. 
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caspase-3 protein as a result of a 47-bp deletion in the corresponding gene [135].  In 
contrast to BaF3 cells, no increase in Wee1 protein, Tyr15-Cdc2 phosphorylation, total 
p34Cdc2 or changes in PARP were observed when MCF7 cells were treated with the 
caspase-3 inhibitor Ac-DEVD-CHO,  the caspase-7 inhibitor Ac-LEHD-CHO or the pan-
caspase inhibitor Z-VAD-FMK, strongly suggesting that caspase inhibition is required 
for Survivin-mediated enhancement of phospho-Tyr15-Cdc2 and Wee1 protein levels 
(Figure 22).  The fact that the pan-caspase inhibitor and caspase-7 inhibitors did not 
affect Wee1 protein levels or Tyr15 p34Cdc2 phosphorylation suggests that the effects 
seen in the BaF3 cells are specific to caspase-3. 
Destabilization of Survivin Abrogates the Effect on Wee1 
 Survivin protein is stabilized by interacting with the heatshock protein Hsp90 [22, 
83, 145].  We therefore evaluated whether blocking Survivin-Hsp90 interaction would 
block increased Cdc2 phosphorylation to further confirm a specific role for Survivin in 
increasing Cdc2 phosphorylation and Wee1 protein levels.  BaF3 cells over-expressing 
wt-Survivin were treated with the Hsp90 inhibitor AICAR or DMSO vehicle for 1, 2, 5 or 
6 hours and lysates analyzed for Tyr15-Cdc2 phosphorylation levels.  No effect of 
AICAR on phospho-Tyr15-Cdc2 levels were observed during the first 2 hours of 
treatment, however at 5 hours the levels of phospho-Tyr15-Cdc2 in BaF3 cells treated 
with the Hsp90 inhibitor were significantly lower then untreated cells.  The effect was 
even more pronounced at 6 hours, where essentially no phospho-Tyr15-Cdc2 was 
detected (Figure 23).  Consistent with the destabilizing effects of Hsp90 inhibitors on  
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Figure 22 
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Figure 22.  Treatment of MCF7 Cells with Caspase Inhibitors Has No Effect on 
Phospho-Tyr15-Cdc2 or Wee1 Protein Levels.  MCF7 cells were harvested by 
trypsinization, washed with PBS, counted and plated at 2.5 x 106 cells in 10 cm tissue 
culture plates for 24 hours in α-MEM media.  Cells were then treated with Ac-DEVD-
CHO, Ac-LEHD-CHO, Z-VAD-FMK or dmso vehicle control for 2 hours.  The cells 
were harvested, lysates prepared and 100 ug of each sample run on SDS-PAGE for 
immunoblotting analysis of PARP, Wee1, β-actin, phospho-Tyrosine-15 p34Cdc2, total 
Cdc2, caspase3 and Survivin levels.  Densitometric analysis for Wee1 standardized to β-
actin and phospho-Tyr15-Cdc2 standardized to total Cdc2 are shown under the respective 
blots and expressed relative to vehicle control set at 1.0.  Data are representative of 3 
experiments with similar results. 
. 
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Figure 23 
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Figure 23.  Inhibition of Hsp90 by AICAR Treatment Decreases Phospho-Tyr15-
Cdc2 Levels in wt-Survivin Over-Expressing Cells.  Exponentially growing wt-
Survivin transduced BaF3 cells were harvested, washed with PBS, counted and plated at 
2.5x106 cells per well in 6-well tissue culture plates.  Cells were treated with the Hsp90 
inhibitor AICAR (25 uM) or dmso vehicle control for 1, 2, 5 or 6 hours.  At each time 
point control and AICAR treated cells were harvested, lysates prepared and 100 ug of 
each sample run on SDS-PAGE for immunoblotting analysis of phosphoTyrosine-15 
p34Cdc2, Survivin and β-actin levels.  A plot of the densitometric analysis for the ratios 
of phosphoTyrosine-15 p34Cdc2 (pTyr15 p34Cd2), Survivin and β-actin for untreated 
cells relative to AICAR treated cells in each time point is shown below the blot. 
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Survivin protein stability, Survivin protein levels were reduced coincident with reduction 
in phospho-Tyr15-Cdc2.   
In similar fashion, treatment of BaF3 cells expressing wt-Survivin with 100 nM 
17-AAG, a Geldanamycin-derivative, that blocks the Hsp90 ATP-binding site, resulted  
in a decrease in Wee1 protein (52%),  phospho-Tyr15-Cdc2 (82%), Survivin (68%) and 
whole PARP levels (67%) after 24 hours treatment coincident with reduced levels of 
Hsp90 protein (67%) (Figure 24). 
p21cip1/waf1 is Elevated in wt-Survivin Over-Expressing BaF3 Cells 
 Previous studies by our laboratory indicate that the CDKI p21cip1/waf1 forms an 
axis with Survivin and is necessary in part for some of its effects.  We compared MIEG 
and wt-Survivin transduced BaF3 cells and observed an increase in p21, whole PARP, 
phospho-Tyr15-Cdc2 and Survivin levels in wt-Survivin transduced cells compared to 
MIEG control (Figure 25).  It has been suggested that p21 binds to procaspase-3 to help 
inhibit its cleavage and activation but is also a target of caspase-3 mediated cleavage.  
Therefore, Survivin may have the same effect on p21 levels as Wee1.  Since p21 also 
binds to and inhibits p34Cdc2, Survivin-mediated p21 up-regulation may be another 
pathway involved in Survivin-mediated enhancement of Wee1. 
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Figure 24 
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Figure 24.  17-AAG Treatment of wt-Survivin Over-Expressing BaF3 Cells.  
Exponentially growing wt-Survivin transduced BaF3 cells were treated, harvested, 
washed with PBS, counted and 2.5 x 106 cells per well cultured in serum-free RPMI in 6-
well tissue culture plates.  Cells were treated with 100 nM 17-AAG or DMSO vehicle 
control for 24 hrs and cells harvested, lysates prepared and 100 ug of each sample run on 
SDS-PAGE for immunoblotting of phospho-Tyr15-Cdc2, PARP, Survivin, Hsp90, β-
Actin and Survivin levels.  Relative expression of each protein in 17-AAG treated cells as 
compared to vehicle control is expressed as delta percentage change.  Lysates from cells 
at baseline (time 0 hr) are included as controls. 
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Figure 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
Figure 25.  p21cip1/waf1 Protein Elevation Correlates with Increased Survivin and 
Phospho-Tyr15-Cdc2 Levels.  Exponentially growing MIEG control and wt-Survivin 
transduced BaF3 cells were harvested, lysates prepared and 100 ug (top 3 blots) or 50 ug 
(bottom 3 blots) of each sample run on SDS-PAGE for immunoblotting analysis of 
p21cip1/waf1, PARP, GAPDH, phospho-Tyr15-Cdc2 and Survivin levels.   
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Unified Model of Survivin-Mediated Increase in Phospho-Tyr15-Cdc2 and Inhibition of 
Apoptosis 
 Signaling pathway inhibition studies suggest that signaling through the Ras-Raf-
Mek-Erk or PI3K-Akt pathways maintains Survivin levels, which leads to increased 
inhibition of caspase-3 activity.  This decrease in caspase-3 activity in turn results in an  
increase of Wee1 protein levels, which leads to an increase in Cdc2-Tyr15 inhibitory 
phosphorylation.  Our data also shows that p21cip1/waf1 levels are increased, and as a result 
may help inhibit both caspase-3 activation and Cdc2 activity.  We therefore have defined 
a pathway through which Survivin inhibition of caspase-3 activity maintains or elevates 
the Wee1 kinase that inhibits the apoptotic function of the Cdc2 kinase thereby 
promoting cell proliferation and survival (Figure 26). 
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Figure 26 
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Figure 26.  Unifying Model of Survivin’s Effect on Cdc2 Inactivation and Inhibition 
of Apoptosis.  Increase in Survivin protein levels results in increased inhibition of 
caspase-3 activity.  In turn, there is an increase in the protein levels of Wee1 kinase 
which phosphorylates cytoplasmic Cdc2 on Tyrosine-15 thereby preventing dysregulated 
Cdc2 activation and ultimately helping to evade apoptosis and promote cell survival.  
Since Survivin over-expression also elevates protein levels of  p21cip1/waf1, the literature 
suggests this increase should also aid anti-apoptotic activity through binding of 
p21cip1/waf1  to procaspase-3 and blociking caspase-3 activation as well as physically 
interacting with and inhibiting Cdc2.   
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DISCUSSION 
A number of studies show that Survivin over-expression confers resistance to 
apoptosis that is mediated through the inhibition of proapoptotic proteins such as 
caspases 3, 7 and 9 [8, 20, 146].  We have found that Survivin over-expression also 
increases phosphorylation of p34Cdc2 on Tyrosine-15.  Although Cdc2 can promote 
mitosis, it can also mediate apoptosis, and phosphorylation of p34Cdc2 at Tyrosine-15 
inactivates Cdc2 blocking its pro-apoptotic activity [131, 137-140].  Increased phospho-
Tyr15-Cdc2 is consistent both with the role of Cdc2 and the action of the anti-apoptotic 
protein Survivin.  However, since Survivin does not contain instrinc kinase activity, it is 
not clear how Cdc2 phosphorylation is achieved.  Herein, we show that Survivin 
increases the level of the Wee1 kinase that phosphorylates Cdc2 by blocking Wee1 
degradation by caspase-3.  The increase in Wee1 protein and and Tyrosine-15 
phosphorylation of Cdc2 directly correlates with increased survival in cells expressing 
ectopic wild-type Survivin.  To our knowledge this is the first report demonstrating a 
functional link between the Wee1 kinase and Survivin.      
 A functional link between Survivin and Cdc2 has been previously reported [18], 
however  cross-talk between the two proteins has recently come into question.  Several 
reports show a correlation between Cdc2 activation and apoptosis [131, 137-140], thus it 
makes sense that Cdc2 inactivation correlates with Survivin over-expression.  However, 
an association between induction of increased Survivin and an increase in p34Cdc2 
activation in response to ethanol in a gastric epithelial cell line model was recently 
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reported [147].  Although these findings seem contradictory to our findings in normal 
hematopoietic cells, differences in normal versus transformed cells could be responsible.  
Also, in the gastric epithelial model it is assumed that active Cdc2 results in increased 
Survivin stabilization and thus the two are upregulated simultaneously.  However, we 
show that an increase in Survivin expression in turn has a down-regulatory effect on 
Cdc2 activity through Wee1 kinase protection from caspase-3 mediated degradation, thus 
forming a negative feedback loop resulting in enhanced evasion of apoptosis.  Our 
proposed regulatory role of Survivin and p34Cdc2 is consistent with our previous report 
that Survivin functions as a regulatory element in the Mdm2-p53 pathway, where it 
reduces p53 protein and mRNA through protection of Mdm2 from caspase-mediated 
degradation [61]. 
 In further support of the role of Survivin in increasing phosphorylation of Tyr15-
Cdc2 as a mechanism to increase cell survival, we used a leukemia cell model that 
increases Survivin protein levels through constitutively active ITD-Flt3 mutant receptors.  
This model affords the opportunity to study Survivin and its effects on Cdc2-Tyr15 
phosphorylation in a manner that more closely resembles Survivin up-regulation in vivo.  
We observed a significant increase in phospho-Tyr15-Cdc2 levels that correlated with 
increased cell survival in cells transduced with the ITD-Flt3 mutants compared to control 
cells transduced with wt-Flt3 when we cultured these cells in pro-apoptotic conditions.  
These results strongly support the link between Survivin, its effect on Tyr15-Cdc2 
phosphorylation and increased evasion from apoptosis.   
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 Although Survivin is associated with inhibition of caspase activity, whether it 
directly binds and inhibits caspase-3 directly is not clear [148-151].  Nevertheless, over-
expression of wt-Survivin in our model system resulted in an increase in whole PARP 
levels as compared to cells over-expressing vector alone and PARP cleavage is an 
established measure of active caspase-3 [152].  We have also shown that ectopic Survivin 
is sufficient to maintain phospho-Tyr15-Cdc2 levels even in the presence of an 
exogenous specific caspase-3 inhibitor Ac-DEVD-CHO and that this effect is absent in 
caspase-3 deficient cells.  Taken together these results strongly support Survivin-
mediated caspase-3 inhibition, however they do not prove whether this represents a direct 
effect on caspase-3.  We also show that Survivin over-expression is sufficient to maintain 
higher levels of Wee1 kinase compared to vector-control cells even in the presence of 
caspase inhibition, and present strong evidence that this effect is mediated through 
caspase-3 inhibition, although we cannot rule out the involvement of other caspases, at 
least in BaF3 cells.  However, the lack of increase in Wee1 and phospho-Tyr15-Cdc2 
levels in MCF7 cells deficient only in caspase-3 strongly suggests that caspase-3 is the 
primary caspase mediating protection of Wee1.  It has been reported that the Wee1 kinase 
is a caspase-3 target and is associated with resistance to apoptosis [130, 131], similar to 
Survivin.  Thus our finding that Wee1 kinase is upregulated by wt-Survivin over-
expression through caspase-3 inhibition is consistent with the mechanism of both 
proteins. 
 86 
 
Caspase-3 has been reported to play a role in the maintenance of the 
hematopoietic stem cell (HSC) pool [75].  HSCs deficient in caspase-3 show an 
accelerated proliferation and retarded differentiation.  This finding is consistent with our 
past studies that Survivin is up-regulated in response to growth factors in quiescent 
CD34+ cells and required for their entry into cell cycle [3, 73, 134].  In addition, using a 
conditional Survivin knockout mouse model, Survivin deletion results in significant 
impairment in HSC number and HSC function (Fukuda S. and Pelus, L.M. unpublished).  
Taken together these studies indicate that Survivin and caspase-3 are intimately involved 
in HSC function.  Increased caspase-3 inhibition by Survivin maintains the stem cell pool 
and loss of Survivin protein with subsequent increased caspase-3 activity results in loss 
of HSC function and perhaps increased cell differentiation.  Very little is known about 
the role of Wee1 kinase in hematopoiesis, and it will be interesting to determine how it is 
regulated in HSCs and in their differentiated progeny.  Since Survivin is up-regulated 
endogenously in HSCs and initiates proliferation, our present results suggest that 
regulation of Wee1 protein in these cells is likely directly correlated with Survivin levels.  
In addition, reports have shown that regulation of Wee1 correlates with cell survival 
[104, 130, 131, 153, 154].  Thus, evaluation of whether inhibition of Wee1 kinase in 
Survivin-over-expressing cancers would down-regulate inhibition of apoptosis could 
identify a novel and effective chemotherapeutic strategy. 
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SUMMARY 
 In chapter one, we showed that Survivin over-expression results in increased 
Tyrosine-15 phosphorylation of p34Cdc2 kinase and this increase correlates with cell 
survival and proliferation.  We were able to confirm these findings in both BaF3 cells that 
were retrovirally transduced with the wt-Survivin gene as well as in cells that over-
expressed Survivin through retroviral transduction of constitutively active tyrosine kinase 
receptors (ITD-Flt3).  This finding is important because it implies a mutual signaling loop 
between Survivin and p34Cdc2, rather than the proposed pathway whereby Cdc2 together 
with Cyclin B1 phosphorylates Survivin on Threonine-34 and stabilize the protein.  Since 
Survivin contains no instrinsic kinase activity we verified that this increase in 
phosphorylation is not due to a build-up of cells in S-phase of cell cycle, where p34Cdc2 
is known to be inactive, but rather to an increase in Wee1 kinase protein levels.  
However, we could not detect a direct association between Wee1 and Survivin in our 
murine cell line or in human Jurkat-T cells, which would have implicated Survivin as a 
scaffold protein between p34Cdc2 and Wee1.   
 In chapter two, we showed that Survivin’s effect on Wee1 kinase is caspase-3 
dependent and that over-expression of wt-Survivin is sufficient to maintain 
phosphorylation of Tyrosine-15 of p34Cdc2 even in the presence of additional 
pharmacological caspase-3 inhibition.  This was further proven in MCF7 cells that lack 
endogenous caspase-3, where pharmacological caspase inhibition was unable to increase 
Cdc2-Tyr15 phosphorylation.  In order to study how disruption of Survivin would affect 
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the observed effects we utilized two Hsp90 inhibitors AICAR and 17-AAG that 
destabilize Survivin.  Both inhibitors decreased phospho-Tyr15-Cdc2 levels, indicating 
that it is possible to block the effect of Survivin on Cdc2 phosphorylation.  We also found 
that p21cip1/waf1 is elevated in cells over-expressing Survivin, which is another target of 
caspase-3 and known to inhibit Cdc2 activity, potentially implicating another player in 
this process.  
 In summary, our results suggest that Survivin over-expression mediates protection 
of the Wee1 kinase through inhibition of caspase-3, which in turn leads to an increase in 
phospho-Tyr15-Cdc2 levels.  In the absence of Survivin, caspase-3 is not inhibited, Wee1 
is degraded and Cdc2 is activated or kept active and apoptosis is initiated.  It is possible 
that other proteins that affect p34Cdc2 activity, particularly p21Cip1/Waf1 that can inhibit 
Cdc2 [155], and is also a caspase-3 target [156], play an important role in the 
proliferation of normal hematopoietic stem cells by Survivin [74] may play a role in the 
anti-apoptotic Survivin-caspase-3-Wee1-Cdc2 axis we have described. 
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FUTURE STUDIES 
 
 In order to study the requirement of Wee1 kinase in Survivin-mediated apoptotic 
evasion, the use of retroviral vectors to incorporate both wt-Survivin or a dominant-dn-
Survivin mutant in combination with a wt-Wee1 or a Wee1 lacking its kinase domain 
could prove useful.  Primary cells could be transduced with the abovementioned viral 
vectors and apoptotis measured by Annexin V/PI staining, caspase-3 activity assay, 
TUNEL assays and viable cell counts, either without stimulation or within cytokine and 
serum-depleted conditions.  Another way to stimulate apoptosis in these cells would be 
by incubating them with FasL or agonist Fas-antibody and then measuring their response.  
This would establish a more definitive role for Wee1 in Survivin-mediated apoptosis.   
 Since we have seen that Survivin up-regulates total Wee1 protein levels, it would 
be worthwhile to evaluate the kinetic activity of Wee1 in wt-Survivin over-expressing 
cells compared to control cells.  MIEG and wt-Survivin transduced cells could be 
harvested during log-phase of their growth in culture, lysates prepared and Wee1 kinase 
immunoprecipitated.  Equal amounts of immunoprecipitated lysate could then be 
incubated with small amounts of total lysate from control cells to allow Wee1 to 
phosphorylate p34Cdc2 on Tyr15, then the resulting lysates run on SDS-PAGE gels and 
immunoblotted for phospho-Tyr15-Cdc2 levels.  Should they show comparable amounts 
of kinase activity then having more total protein in wt-Survivin over-expressing cells 
would result in more kinase activity as a result of increase in total protein.  However, 
should the experiment result in higher kinase levels in the wt-Survivin over-expressing 
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cells, further experiments could be performed studying the pathways potentially 
regulating Wee1 kinase activity and how Survivin up-regulation is affecting them. 
 Since we have conditional knockout mice for Survivin, these mice could be used 
to determine if Wee1 over-expression can compensate for the loss of Survivin in 
maintaining the hematopoietic stem cell compartment.  A competitive repopulation assay 
could be employed with hematopoietic stem and progenitor cells taken from the Survivin 
conditional knockouts, the latter could be transduced with vector, Wee1 kinase or kinase-
dead Wee1 retroviral vectors and transplanted into bone marrow ablated recipient mice.  
The ability or inability of the Survivin-/Wee1+ cells would help better understand the 
relationship between Wee1 and Survivin that we have defined. 
 The use of p21cip1/waf1 knockout mice would help determine the necessity of p21 in 
Survivin’s effect on Wee1, p34Cdc2 and overall survival.  Although our laboratory has 
already published the necessity of the p21-Survivin axis on survival in a hematopoietic 
context [74], we have not studied what effect the loss of p21 would have on Wee1 in cells 
over-expressing Survivin.  Either transient and permanent ectopic expression of Survivin 
in p21-/- cells and measurement of Wee1 protein levels would help define their 
relationship.  
 
 
 
 
 
 
 
 91 
 
REFERENCES 
 
1. Ambrosini, G., C. Adida, and D.C. Altieri, A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma. Nat Med, 1997. 3(8): p. 917-21. 
2. Adida, C., P.L. Crotty, J. McGrath, D. Berrebi, J. Diebold, and D.C. Altieri, 
Developmentally regulated expression of the novel cancer anti-apoptosis gene 
survivin in human and mouse differentiation. Am J Pathol, 1998. 152(1): p. 43-9. 
3. Fukuda, S. and L.M. Pelus, Regulation of the inhibitor-of-apoptosis family 
member survivin in normal cord blood and bone marrow CD34(+) cells by 
hematopoietic growth factors: implication of survivin expression in normal 
hematopoiesis. Blood, 2001. 98(7): p. 2091-100. 
4. Kornacker, M., M.R. Verneris, B. Kornacker, C. Scheffold, and R.S. Negrin, 
Survivin expression correlates with apoptosis resistance after lymphocyte 
activation and is found preferentially in memory T cells. Immunol Lett, 2001. 
76(3): p. 169-73. 
5. Marconi, A., K. Dallaglio, R. Lotti, C. Vaschieri, F. Truzzi, F. Fantini, and C. 
Pincelli, Survivin identifies keratinocyte stem cells and is downregulated by anti-
beta1 integrin during anoikis. Stem Cells, 2007. 25(1): p. 149-55. 
6. Jiang, Y., A. de Bruin, H. Caldas, J. Fangusaro, J. Hayes, E.M. Conway, M.L. 
Robinson, and R.A. Altura, Essential role for survivin in early brain development. 
J Neurosci, 2005. 25(30): p. 6962-70. 
7. Kobayashi, K., M. Hatano, M. Otaki, T. Ogasawara, and T. Tokuhisa, Expression 
of a murine homologue of the inhibitor of apoptosis protein is related to cell 
proliferation. Proc Natl Acad Sci U S A, 1999. 96(4): p. 1457-62. 
8. Li, F., G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, and D.C. 
Altieri, Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 
1998. 396(6711): p. 580-4. 
9. Sampath, J. and L.M. Pelus, Alternative splice variants of survivin as potential 
targets in cancer. Curr Drug Discov Technol, 2007. 4(3): p. 174-91. 
10. Altieri, D.C., Survivin, cancer networks and pathway-directed drug discovery. 
Nat Rev Cancer, 2008. 8(1): p. 61-70. 
11. Mellai, M., V. Caldera, A. Patrucco, L. Annovazzi, and D. Schiffer, Survivin 
expression in glioblastomas correlates with proliferation, but not with apoptosis. 
Anticancer Res, 2008. 28(1A): p. 109-18. 
12. Jiang, L.B., X.Q. Liu, B. Li, X.J. He, Y.L. Jin, L.Q. Li, F. Gao, and N.L. Wang, 
Heat shock proteins and survivin: relationship and effects on proliferation index 
of retinoblastoma cells. Histol Histopathol, 2008. 23(7): p. 827-31. 
13. Ambrosini, G., C. Adida, G. Sirugo, and D.C. Altieri, Induction of apoptosis and 
inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998. 
273(18): p. 11177-82. 
14. Li, F. and D.C. Altieri, Transcriptional analysis of human survivin gene 
expression. Biochem J, 1999. 344 Pt 2: p. 305-11. 
 92 
 
15. Xu, R., P. Zhang, J. Huang, S. Ge, J. Lu, and G. Qian, Sp1 and Sp3 regulate basal 
transcription of the survivin gene. Biochem Biophys Res Commun, 2007. 356(1): 
p. 286-92. 
16. Chantalat, L., D.A. Skoufias, J.P. Kleman, B. Jung, O. Dideberg, and R.L. 
Margolis, Crystal structure of human survivin reveals a bow tie-shaped dimer 
with two unusual alpha-helical extensions. Mol Cell, 2000. 6(1): p. 183-9. 
17. Verdecia, M.A., H. Huang, E. Dutil, D.A. Kaiser, T. Hunter, and J.P. Noel, 
Structure of the human anti-apoptotic protein survivin reveals a dimeric 
arrangement. Nat Struct Biol, 2000. 7(7): p. 602-8. 
18. O'Connor, D.S., D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, 
P.C. Marchisio, and D.C. Altieri, Regulation of apoptosis at cell division by 
p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A, 2000. 97(24): p. 
13103-7. 
19. Bolton, M.A., W. Lan, S.E. Powers, M.L. McCleland, J. Kuang, and P.T. 
Stukenberg, Aurora B kinase exists in a complex with survivin and INCENP and 
its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol 
Cell, 2002. 13(9): p. 3064-77. 
20. Song, Z., X. Yao, and M. Wu, Direct interaction between survivin and 
Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-
induced apoptosis. J Biol Chem, 2003. 278(25): p. 23130-40. 
21. Rodriguez, J.A., S.W. Span, C.G. Ferreira, F.A. Kruyt, and G. Giaccone, CRM1-
mediated nuclear export determines the cytoplasmic localization of the 
antiapoptotic protein Survivin. Exp Cell Res, 2002. 275(1): p. 44-53. 
22. Fortugno, P., E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P.C. Marchisio, 
W.C. Sessa, and D.C. Altieri, Regulation of survivin function by Hsp90. Proc Natl 
Acad Sci U S A, 2003. 100(24): p. 13791-6. 
23. Wheatley, S.P., A. Carvalho, P. Vagnarelli, and W.C. Earnshaw, INCENP is 
required for proper targeting of Survivin to the centromeres and the anaphase 
spindle during mitosis. Curr Biol, 2001. 11(11): p. 886-90. 
24. Wheatley, S.P., A.J. Henzing, H. Dodson, W. Khaled, and W.C. Earnshaw, 
Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential 
for its localization and binding to inner centromere protein (INCENP) in vivo. J 
Biol Chem, 2004. 279(7): p. 5655-60. 
25. Stauber, R.H., W. Mann, and S.K. Knauer, Nuclear and cytoplasmic survivin: 
molecular mechanism, prognostic, and therapeutic potential. Cancer Res, 2007. 
67(13): p. 5999-6002. 
26. Mahotka, C., J. Liebmann, M. Wenzel, C.V. Suschek, M. Schmitt, H.E. Gabbert, 
and C.D. Gerharz, Differential subcellular localization of functionally divergent 
survivin splice variants. Cell Death Differ, 2002. 9(12): p. 1334-42. 
 
 
 93 
 
27. Noton, E.A., R. Colnaghi, S. Tate, C. Starck, A. Carvalho, P. Ko Ferrigno, and 
S.P. Wheatley, Molecular analysis of survivin isoforms: evidence that 
alternatively spliced variants do not play a role in mitosis. J Biol Chem, 2006. 
281(2): p. 1286-95. 
28. Mahotka, C., M. Wenzel, E. Springer, H.E. Gabbert, and C.D. Gerharz, Survivin-
deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor 
survivin with different antiapoptotic properties. Cancer Res, 1999. 59(24): p. 
6097-102. 
29. Knauer, S.K., C. Bier, P. Schlag, J. Fritzmann, W. Dietmaier, F. Rodel, L. Klein-
Hitpass, A.F. Kovacs, C. Doring, M.L. Hansmann, W.K. Hofmann, M. Kunkel, C. 
Brochhausen, K. Engels, B.M. Lippert, W. Mann, and R.H. Stauber, The survivin 
isoform survivin-3B is cytoprotective and can function as a chromosomal 
passenger complex protein. Cell Cycle, 2007. 6(12): p. 1502-9. 
30. Li, F., Role of survivin and its splice variants in tumorigenesis. Br J Cancer, 2005. 
92(2): p. 212-6. 
31. Islam, A., H. Kageyama, K. Hashizume, Y. Kaneko, and A. Nakagawara, Role of 
survivin, whose gene is mapped to 17q25, in human neuroblastoma and 
identification of a novel dominant-negative isoform, survivin-beta/2B. Med 
Pediatr Oncol, 2000. 35(6): p. 550-3. 
32. Mahotka, C., T. Krieg, A. Krieg, M. Wenzel, C.V. Suschek, M. Heydthausen, 
H.E. Gabbert, and C.D. Gerharz, Distinct in vivo expression patterns of survivin 
splice variants in renal cell carcinomas. Int J Cancer, 2002. 100(1): p. 30-6. 
33. Krieg, A., C. Mahotka, T. Krieg, H. Grabsch, W. Muller, S. Takeno, C.V. 
Suschek, M. Heydthausen, H.E. Gabbert, and C.D. Gerharz, Expression of 
different survivin variants in gastric carcinomas: first clues to a role of survivin-
2B in tumour progression. Br J Cancer, 2002. 86(5): p. 737-43. 
34. Yamada, Y., T. Kuroiwa, T. Nakagawa, Y. Kajimoto, T. Dohi, H. Azuma, M. 
Tsuji, K. Kami, and S. Miyatake, Transcriptional expression of survivin and its 
splice variants in brain tumors in humans. J Neurosurg, 2003. 99(4): p. 738-45. 
35. Meng, H., C.D. Lu, Y.L. Sun, D.J. Dai, S.W. Lee, and N. Tanigawa, Expression 
level of wild-type survivin in gastric cancer is an independent predictor of 
survival. World J Gastroenterol, 2004. 10(22): p. 3245-50. 
36. Takashima, H., T. Nakajima, M. Moriguchi, S. Sekoguchi, T. Nishikawa, T. 
Watanabe, T. Katagishi, H. Kimura, M. Minami, Y. Itoh, K. Kagawa, and T. 
Okanoue, In vivo expression patterns of survivin and its splicing variants in 
chronic liver disease and hepatocellular carcinoma. Liver Int, 2005. 25(1): p. 77-
84. 
37. Vegran, F., R. Boidot, C. Oudin, J.M. Riedinger, and S. Lizard-Nacol, Distinct 
expression of Survivin splice variants in breast carcinomas. Int J Oncol, 2005. 
27(4): p. 1151-7. 
 94 
 
38. Cheng, Z.J., L.H. Hu, W.R. Fu, and Q. Zhang, [Expression of survivin and its 
splice variants in gastric cancer]. Zhonghua Bing Li Xue Za Zhi, 2008. 37(2): p. 
130-1. 
39. Boidot, R., F. Vegran, and S. Lizard-Nacol, Predictive value of survivin 
alternative transcript expression in locally advanced breast cancer patients 
treated with neoadjuvant chemotherapy. Int J Mol Med, 2009. 23(2): p. 285-91. 
40. Caldas, H., Y. Jiang, M.P. Holloway, J. Fangusaro, C. Mahotka, E.M. Conway, 
and R.A. Altura, Survivin splice variants regulate the balance between 
proliferation and cell death. Oncogene, 2005. 24(12): p. 1994-2007. 
41. Dohi, T., E. Beltrami, N.R. Wall, J. Plescia, and D.C. Altieri, Mitochondrial 
survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest, 2004. 
114(8): p. 1117-27. 
42. Li, F. and X. Ling, Survivin study: an update of "what is the next wave"? J Cell 
Physiol, 2006. 208(3): p. 476-86. 
43. Song, Z. and M. Wu, Identification of a novel nucleolar localization signal and a 
degradation signal in Survivin-deltaEx3: a potential link between nucleolus and 
protein degradation. Oncogene, 2005. 24(16): p. 2723-34. 
44. Caldas, H., L.E. Honsey, and R.A. Altura, Survivin 2alpha: a novel Survivin 
splice variant expressed in human malignancies. Mol Cancer, 2005. 4(1): p. 11. 
45. Badran, A., A. Yoshida, K. Ishikawa, T. Goi, A. Yamaguchi, T. Ueda, and M. 
Inuzuka, Identification of a novel splice variant of the human anti-apoptopsis 
gene survivin. Biochem Biophys Res Commun, 2004. 314(3): p. 902-7. 
46. Aggarwal, B.B., U. Bhardwaj, and Y. Takada, Regulation of TRAIL-induced 
apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm, 2004. 67: 
p. 453-83. 
47. Li, P., D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, 
and X. Wang, Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 
complex initiates an apoptotic protease cascade. Cell, 1997. 91(4): p. 479-89. 
48. Cain, K., Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug 
Metab Rev, 2003. 35(4): p. 337-63. 
49. Zou, H., W.J. Henzel, X. Liu, A. Lutschg, and X. Wang, Apaf-1, a human protein 
homologous to C. elegans CED-4, participates in cytochrome c-dependent 
activation of caspase-3. Cell, 1997. 90(3): p. 405-13. 
50. Cain, K., S.B. Bratton, and G.M. Cohen, The Apaf-1 apoptosome: a large 
caspase-activating complex. Biochimie, 2002. 84(2-3): p. 203-14. 
51. Oberst, A., C. Bender, and D.R. Green, Living with death: the evolution of the 
mitochondrial pathway of apoptosis in animals. Cell Death Differ, 2008. 15(7): p. 
1139-46. 
52. Enari, M., H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata, A 
caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor 
ICAD. Nature, 1998. 391(6662): p. 43-50. 
 95 
 
53. Conway, E.M., S. Pollefeyt, M. Steiner-Mosonyi, W. Luo, A. Devriese, F. Lupu, 
F. Bono, N. Leducq, F. Dol, P. Schaeffer, D. Collen, and J.M. Herbert, Deficiency 
of survivin in transgenic mice exacerbates Fas-induced apoptosis via 
mitochondrial pathways. Gastroenterology, 2002. 123(2): p. 619-31. 
54. Tamm, I., Y. Wang, E. Sausville, D.A. Scudiero, N. Vigna, T. Oltersdorf, and J.C. 
Reed, IAP-family protein survivin inhibits caspase activity and apoptosis induced 
by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 1998. 58(23): 
p. 5315-20. 
55. Fornaro, M., J. Plescia, S. Chheang, G. Tallini, Y.M. Zhu, M. King, D.C. Altieri, 
and L.R. Languino, Fibronectin protects prostate cancer cells from tumor 
necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol 
Chem, 2003. 278(50): p. 50402-11. 
56. Colnaghi, R., C.M. Connell, R.M. Barrett, and S.P. Wheatley, Separating the 
anti-apoptotic and mitotic roles of survivin. J Biol Chem, 2006. 281(44): p. 
33450-6. 
57. Knauer, S.K., O.H. Kramer, T. Knosel, K. Engels, F. Rodel, A.F. Kovacs, W. 
Dietmaier, L. Klein-Hitpass, N. Habtemichael, A. Schweitzer, J. Brieger, C. 
Rodel, W. Mann, I. Petersen, T. Heinzel, and R.H. Stauber, Nuclear export is 
essential for the tumor-promoting activity of survivin. FASEB J, 2007. 21(1): p. 
207-16. 
58. Mesri, M., N.R. Wall, J. Li, R.W. Kim, and D.C. Altieri, Cancer gene therapy 
using a survivin mutant adenovirus. J Clin Invest, 2001. 108(7): p. 981-90. 
59. Blanc-Brude, O.P., M. Mesri, N.R. Wall, J. Plescia, T. Dohi, and D.C. Altieri, 
Therapeutic targeting of the survivin pathway in cancer: initiation of 
mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin 
Cancer Res, 2003. 9(7): p. 2683-92. 
60. McKay, T.R., S. Bell, T. Tenev, V. Stoll, R. Lopes, N.R. Lemoine, and I.A. 
McNeish, Procaspase 3 expression in ovarian carcinoma cells increases survivin 
transcription which can be countered with a dominant-negative mutant, survivin 
T34A; a combination gene therapy strategy. Oncogene, 2003. 22(23): p. 3539-47. 
61. Wang, Z., S. Fukuda, and L.M. Pelus, Survivin regulates the p53 tumor 
suppressor gene family. Oncogene, 2004. 23(49): p. 8146-53. 
62. Fukuda, S. and L.M. Pelus, Activated H-Ras regulates hematopoietic cell survival 
by modulating Survivin. Biochem Biophys Res Commun, 2004. 323(2): p. 636-
44. 
63. Suzuki, A., M. Hayashida, T. Ito, H. Kawano, T. Nakano, M. Miura, K. Akahane, 
and K. Shiraki, Survivin initiates cell cycle entry by the competitive interaction 
with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene, 2000. 
19(29): p. 3225-34. 
64. Jeyaprakash, A.A., U.R. Klein, D. Lindner, J. Ebert, E.A. Nigg, and E. Conti, 
Structure of a Survivin-Borealin-INCENP core complex reveals how 
chromosomal passengers travel together. Cell, 2007. 131(2): p. 271-85. 
 96 
 
65. Vagnarelli, P. and W.C. Earnshaw, Chromosomal passengers: the four-
dimensional regulation of mitotic events. Chromosoma, 2004. 113(5): p. 211-22. 
66. Tanaka, T.U., Chromosome bi-orientation on the mitotic spindle. Philos Trans R 
Soc Lond B Biol Sci, 2005. 360(1455): p. 581-9. 
67. Gassmann, R., A. Carvalho, A.J. Henzing, S. Ruchaud, D.F. Hudson, R. Honda, 
E.A. Nigg, D.L. Gerloff, and W.C. Earnshaw, Borealin: a novel chromosomal 
passenger required for stability of the bipolar mitotic spindle. J Cell Biol, 2004. 
166(2): p. 179-91. 
68. Sampath, S.C., R. Ohi, O. Leismann, A. Salic, A. Pozniakovski, and H. Funabiki, 
The chromosomal passenger complex is required for chromatin-induced 
microtubule stabilization and spindle assembly. Cell, 2004. 118(2): p. 187-202. 
69. Yang, D., A. Welm, and J.M. Bishop, Cell division and cell survival in the 
absence of survivin. Proc Natl Acad Sci U S A, 2004. 101(42): p. 15100-5. 
70. Castedo, M. and G. Kroemer, [Mitotic catastrophe: a special case of apoptosis]. J 
Soc Biol, 2004. 198(2): p. 97-103. 
71. Mansilla, S., W. Priebe, and J. Portugal, Mitotic catastrophe results in cell death 
by caspase-dependent and caspase-independent mechanisms. Cell Cycle, 2006. 
5(1): p. 53-60. 
72. Vakifahmetoglu, H., M. Olsson, C. Tamm, N. Heidari, S. Orrenius, and B. 
Zhivotovsky, DNA damage induces two distinct modes of cell death in ovarian 
carcinomas. Cell Death Differ, 2008. 15(3): p. 555-66. 
73. Fukuda, S. and L.M. Pelus, Elevation of Survivin levels by hematopoietic growth 
factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells 
before cell cycle entry. Cell Cycle, 2002. 1(5): p. 322-6. 
74. Fukuda, S., C.R. Mantel, and L.M. Pelus, Survivin regulates hematopoietic 
progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent 
pathways. Blood, 2004. 103(1): p. 120-7. 
75. Janzen, V., H.E. Fleming, T. Riedt, G. Karlsson, M.J. Riese, C. Lo Celso, G. 
Reynolds, C.D. Milne, C.J. Paige, S. Karlsson, M. Woo, and D.T. Scadden, 
Hematopoietic stem cell responsiveness to exogenous signals is limited by 
caspase-3. Cell Stem Cell, 2008. 2(6): p. 584-94. 
76. Fukuda, S. and L.M. Pelus, Survivin, a cancer target with an emerging role in 
normal adult tissues. Mol Cancer Ther, 2006. 5(5): p. 1087-98. 
77. Peng, X.C., L. Yang, L.P. Yang, Y.Q. Mao, H.S. Yang, J.Y. Liu, D.M. Zhang, 
L.J. Chen, and Y.Q. Wei, Efficient inhibition of murine breast cancer growth and 
metastasis by gene transferred mouse survivin Thr34-->Ala mutant. J Exp Clin 
Cancer Res, 2008. 27: p. 46. 
78. Ogura, A., Y. Watanabe, D. Iizuka, H. Yasui, M. Amitani, S. Kobayashi, M. 
Kuwabara, and O. Inanami, Radiation-induced apoptosis of tumor cells is 
facilitated by inhibition of the interaction between Survivin and Smac/DIABLO. 
Cancer Lett, 2008. 259(1): p. 71-81. 
 97 
 
79. Ma, X., W. Zheng, D. Wei, Y. Ma, T. Wang, J. Wang, Q. Liu, and S. Yang, High-
level expression, purification and pro-apoptosis activity of HIV-TAT-survivin 
(T34A) mutant to cancer cells in vitro. J Biotechnol, 2006. 123(3): p. 367-78. 
80. Yan, H., J. Thomas, T. Liu, D. Raj, N. London, T. Tandeski, S.A. Leachman, 
R.M. Lee, and D. Grossman, Induction of melanoma cell apoptosis and inhibition 
of tumor growth using a cell-permeable Survivin antagonist. Oncogene, 2006. 
25(52): p. 6968-74. 
81. Zhang, M., N. Mukherjee, R.S. Bermudez, D.E. Latham, M.A. Delaney, A.L. 
Zietman, W.U. Shipley, and A. Chakravarti, Adenovirus-mediated inhibition of 
survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro 
and in vivo. Prostate, 2005. 64(3): p. 293-302. 
82. Whitesell, L., E.G. Mimnaugh, B. De Costa, C.E. Myers, and L.M. Neckers, 
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex 
formation by benzoquinone ansamycins: essential role for stress proteins in 
oncogenic transformation. Proc Natl Acad Sci U S A, 1994. 91(18): p. 8324-8. 
83. Meli, M., M. Pennati, M. Curto, M.G. Daidone, J. Plescia, S. Toba, D.C. Altieri, 
N. Zaffaroni, and G. Colombo, Small-molecule targeting of heat shock protein 90 
chaperone function: rational identification of a new anticancer lead. J Med 
Chem, 2006. 49(26): p. 7721-30. 
84. Sharp, S. and P. Workman, Inhibitors of the HSP90 molecular chaperone: current 
status. Adv Cancer Res, 2006. 95: p. 323-48. 
85. Prodromou, C., S.M. Roe, R. O'Brien, J.E. Ladbury, P.W. Piper, and L.H. Pearl, 
Identification and structural characterization of the ATP/ADP-binding site in the 
Hsp90 molecular chaperone. Cell, 1997. 90(1): p. 65-75. 
86. Schulte, T.W. and L.M. Neckers, The benzoquinone ansamycin 17-allylamino-17-
demethoxygeldanamycin binds to HSP90 and shares important biologic activities 
with geldanamycin. Cancer Chemother Pharmacol, 1998. 42(4): p. 273-9. 
87. Hostein, I., D. Robertson, F. DiStefano, P. Workman, and P.A. Clarke, Inhibition 
of signal transduction by the Hsp90 inhibitor 17-allylamino-17-
demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res, 2001. 
61(10): p. 4003-9. 
88. Weissman, I.L. and J.A. Shizuru, The origins of the identification and isolation of 
hematopoietic stem cells, and their capability to induce donor-specific 
transplantation tolerance and treat autoimmune diseases. Blood, 2008. 112(9): p. 
3543-53. 
89. Shaheen, M.a.B., H.E., Chapter 19: The humoral regulation of hematopoiesis. 4th 
ed. Hematology: Basic Principles and Practice, ed. R. Ed. Hoffman, Benz E, 
Shattil S, Furie B, Cohen H, Silberstein L and McGlave P. 2005: Elsevier 
Churchill Livingston. 
90. Berenson, R.J., R.G. Andrews, W.I. Bensinger, D. Kalamasz, G. Knitter, C.D. 
Buckner, and I.D. Bernstein, Antigen CD34+ marrow cells engraft lethally 
irradiated baboons. J Clin Invest, 1988. 81(3): p. 951-5. 
 98 
 
91. Terstappen, L.W., S. Huang, M. Safford, P.M. Lansdorp, and M.R. Loken, 
Sequential generations of hematopoietic colonies derived from single nonlineage-
committed CD34+CD38- progenitor cells. Blood, 1991. 77(6): p. 1218-27. 
92. Thornley, I., D.R. Sutherland, R. Nayar, L. Sung, M.H. Freedman, and H.A. 
Messner, Replicative stress after allogeneic bone marrow transplantation: 
changes in cycling of CD34+CD90+ and CD34+CD90- hematopoietic 
progenitors. Blood, 2001. 97(6): p. 1876-8. 
93. Fritsch, G., P. Buchinger, D. Printz, F.M. Fink, G. Mann, C. Peters, T. Wagner, 
A. Adler, and H. Gadner, Rapid discrimination of early CD34+ myeloid 
progenitors using CD45-RA analysis. Blood, 1993. 81(9): p. 2301-9. 
94. Kiel, M.J., O.H. Yilmaz, T. Iwashita, C. Terhorst, and S.J. Morrison, SLAM 
family receptors distinguish hematopoietic stem and progenitor cells and reveal 
endothelial niches for stem cells. Cell, 2005. 121(7): p. 1109-21. 
95. Strausfeld, U., J.C. Labbe, D. Fesquet, J.C. Cavadore, A. Picard, K. Sadhu, P. 
Russell, and M. Doree, Dephosphorylation and activation of a p34cdc2/cyclin B 
complex in vitro by human CDC25 protein. Nature, 1991. 351(6323): p. 242-5. 
96. Castedo, M., J.L. Perfettini, T. Roumier, and G. Kroemer, Cyclin-dependent 
kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death 
Differ, 2002. 9(12): p. 1287-93. 
97. Blangy, A., H.A. Lane, P. d'Herin, M. Harper, M. Kress, and E.A. Nigg, 
Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a 
kinesin-related motor essential for bipolar spindle formation in vivo. Cell, 1995. 
83(7): p. 1159-69. 
98. Peter, M., J. Nakagawa, M. Doree, J.C. Labbe, and E.A. Nigg, In vitro 
disassembly of the nuclear lamina and M phase-specific phosphorylation of 
lamins by cdc2 kinase. Cell, 1990. 61(4): p. 591-602. 
99. Kimura, K., M. Hirano, R. Kobayashi, and T. Hirano, Phosphorylation and 
activation of 13S condensin by Cdc2 in vitro. Science, 1998. 282(5388): p. 487-
90. 
100. Smits, V.A. and R.H. Medema, Checking out the G(2)/M transition. Biochim 
Biophys Acta, 2001. 1519(1-2): p. 1-12. 
101. Peters, J.M., The anaphase-promoting complex: proteolysis in mitosis and 
beyond. Mol Cell, 2002. 9(5): p. 931-43. 
102. Nigg, E.A., Mitotic kinases as regulators of cell division and its checkpoints. Nat 
Rev Mol Cell Biol, 2001. 2(1): p. 21-32. 
103. Rudner, A.D. and A.W. Murray, Phosphorylation by Cdc28 activates the Cdc20-
dependent activity of the anaphase-promoting complex. J Cell Biol, 2000. 149(7): 
p. 1377-90. 
104. Heald, R., M. McLoughlin, and F. McKeon, Human wee1 maintains mitotic 
timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. 
Cell, 1993. 74(3): p. 463-74. 
 99 
 
105. Fotedar, R., J. Flatt, S. Gupta, R.L. Margolis, P. Fitzgerald, H. Messier, and A. 
Fotedar, Activation-induced T-cell death is cell cycle dependent and regulated by 
cyclin B. Mol Cell Biol, 1995. 15(2): p. 932-42. 
106. Jin, P., S. Hardy, and D.O. Morgan, Nuclear localization of cyclin B1 controls 
mitotic entry after DNA damage. J Cell Biol, 1998. 141(4): p. 875-85. 
107. Porter, L.A., I.H. Cukier, and J.M. Lee, Nuclear localization of cyclin B1 
regulates DNA damage-induced apoptosis. Blood, 2003. 101(5): p. 1928-33. 
108. Castedo, M., K.F. Ferri, J. Blanco, T. Roumier, N. Larochette, J. Barretina, A. 
Amendola, R. Nardacci, D. Metivier, J.A. Este, M. Piacentini, and G. Kroemer, 
Human immunodeficiency virus 1 envelope glycoprotein complex-induced 
apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-
associated protein-mediated p53 phosphorylation. J Exp Med, 2001. 194(8): p. 
1097-110. 
109. Freeman, R.S., S. Estus, and E.M. Johnson, Jr., Analysis of cell cycle-related gene 
expression in postmitotic neurons: selective induction of Cyclin D1 during 
programmed cell death. Neuron, 1994. 12(2): p. 343-55. 
110. Oberhammer, F.A., K. Hochegger, G. Froschl, R. Tiefenbacher, and M. Pavelka, 
Chromatin condensation during apoptosis is accompanied by degradation of 
lamin A+B, without enhanced activation of cdc2 kinase. J Cell Biol, 1994. 126(4): 
p. 827-37. 
111. Norbury, C., M. MacFarlane, H. Fearnhead, and G.M. Cohen, Cdc2 activation is 
not required for thymocyte apoptosis. Biochem Biophys Res Commun, 1994. 
202(3): p. 1400-6. 
112. Perry, M.E. and A.J. Levine, Tumor-suppressor p53 and the cell cycle. Curr Opin 
Genet Dev, 1993. 3(1): p. 50-4. 
113. Alberts, B., Johnson, A., Lewis J., Raff M., Roberts K. and Walter, P., Molecular 
Biology of the Cell. 4th ed. 2002, New York. 
114. Wang, Y., S.J. Decker, and J. Sebolt-Leopold, Knockdown of Chk1, Wee1 and 
Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. 
Cancer Biol Ther, 2004. 3(3): p. 305-13. 
115. Castedo, M., J.L. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. 
Kroemer, Cell death by mitotic catastrophe: a molecular definition. Oncogene, 
2004. 23(16): p. 2825-37. 
116. Viktorsson, K., R. Lewensohn, and B. Zhivotovsky, Apoptotic pathways and 
therapy resistance in human malignancies. Adv Cancer Res, 2005. 94: p. 143-96. 
117. Ellis, H.M. and H.R. Horvitz, Genetic control of programmed cell death in the 
nematode C. elegans. Cell, 1986. 44(6): p. 817-29. 
118. Hengartner, M.O., R.E. Ellis, and H.R. Horvitz, Caenorhabditis elegans gene ced-
9 protects cells from programmed cell death. Nature, 1992. 356(6369): p. 494-9. 
119. Miura, M., H. Zhu, R. Rotello, E.A. Hartwieg, and J. Yuan, Induction of 
apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog 
of the C. elegans cell death gene ced-3. Cell, 1993. 75(4): p. 653-60. 
 100 
 
120. Fritz, J.H., R.L. Ferrero, D.J. Philpott, and S.E. Girardin, Nod-like proteins in 
immunity, inflammation and disease. Nat Immunol, 2006. 7(12): p. 1250-7. 
121. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, BCL-2 family members and the 
mitochondria in apoptosis. Genes Dev, 1999. 13(15): p. 1899-911. 
122. Li, J. and J. Yuan, Caspases in apoptosis and beyond. Oncogene, 2008. 27(48): p. 
6194-206. 
123. Qin, H., S.M. Srinivasula, G. Wu, T. Fernandes-Alnemri, E.S. Alnemri, and Y. 
Shi, Structural basis of procaspase-9 recruitment by the apoptotic protease-
activating factor 1. Nature, 1999. 399(6736): p. 549-57. 
124. Cardone, M.H., N. Roy, H.R. Stennicke, G.S. Salvesen, T.F. Franke, E. 
Stanbridge, S. Frisch, and J.C. Reed, Regulation of cell death protease caspase-9 
by phosphorylation. Science, 1998. 282(5392): p. 1318-21. 
125. Allan, L.A., N. Morrice, S. Brady, G. Magee, S. Pathak, and P.R. Clarke, 
Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat 
Cell Biol, 2003. 5(7): p. 647-54. 
126. Allan, L.A. and P.R. Clarke, Phosphorylation of caspase-9 by CDK1/cyclin B1 
protects mitotic cells against apoptosis. Mol Cell, 2007. 26(2): p. 301-10. 
127. Lakhani, S.A., A. Masud, K. Kuida, G.A. Porter, Jr., C.J. Booth, W.Z. Mehal, I. 
Inayat, and R.A. Flavell, Caspases 3 and 7: key mediators of mitochondrial events 
of apoptosis. Science, 2006. 311(5762): p. 847-51. 
128. Takizawa, C.G. and D.O. Morgan, Control of mitosis by changes in the 
subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol, 2000. 
12(6): p. 658-65. 
129. Kellogg, D.R., Wee1-dependent mechanisms required for coordination of cell 
growth and cell division. J Cell Sci, 2003. 116(Pt 24): p. 4883-90. 
130. Lei, P., Y. He, W. Shi, J. Peng, S. Wu, H. Zhu, J. Chen, and G. Shen, Effect of 
human WEE1 and stem cell factor on human CD34+ umbilical cord blood cell 
damage induced by chemotherapeutic agents. Acta Biochim Biophys Sin 
(Shanghai), 2007. 39(8): p. 599-607. 
131. Chen, G., L. Shi, D.W. Litchfield, and A.H. Greenberg, Rescue from granzyme B-
induced apoptosis by Wee1 kinase. J Exp Med, 1995. 181(6): p. 2295-300. 
132. Yuan, H., Y.M. Xie, and I.S. Chen, Depletion of Wee-1 kinase is necessary for 
both human immunodeficiency virus type 1 Vpr- and gamma irradiation-induced 
apoptosis. J Virol, 2003. 77(3): p. 2063-70. 
133. Smith, J.J., D.A. Richardson, J. Kopf, M. Yoshida, R.E. Hollingsworth, and S. 
Kornbluth, Apoptotic regulation by the Crk adapter protein mediated by 
interactions with Wee1 and Crm1/exportin. Mol Cell Biol, 2002. 22(5): p. 1412-
23. 
134. Fukuda, S., R.G. Foster, S.B. Porter, and L.M. Pelus, The antiapoptosis protein 
survivin is associated with cell cycle entry of normal cord blood CD34(+) cells 
and modulates cell cycle and proliferation of mouse hematopoietic progenitor 
cells. Blood, 2002. 100(7): p. 2463-71. 
 101 
 
135. Janicke, R.U., M.L. Sprengart, M.R. Wati, and A.G. Porter, Caspase-3 is required 
for DNA fragmentation and morphological changes associated with apoptosis. J 
Biol Chem, 1998. 273(16): p. 9357-60. 
136. Panvichian, R., K. Orth, M.L. Day, K.C. Day, M.J. Pilat, and K.J. Pienta, 
Paclitaxel-associated multimininucleation is permitted by the inhibition of 
caspase activation: a potential early step in drug resistance. Cancer Res, 1998. 
58(20): p. 4667-72. 
137. Shi, L., W.K. Nishioka, J. Th'ng, E.M. Bradbury, D.W. Litchfield, and A.H. 
Greenberg, Premature p34cdc2 activation required for apoptosis. Science, 1994. 
263(5150): p. 1143-5. 
138. Yao, S.L., K.A. McKenna, S.J. Sharkis, and A. Bedi, Requirement of p34cdc2 
kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-
converting enzyme-related proteases. Cancer Res, 1996. 56(20): p. 4551-5. 
139. Shi, L., G. Chen, D. He, D.G. Bosc, D.W. Litchfield, and A.H. Greenberg, 
Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase 
activity in all stages of the cell cycle. J Immunol, 1996. 157(6): p. 2381-5. 
140. Meikrantz, W., S. Gisselbrecht, S.W. Tam, and R. Schlegel, Activation of cyclin 
A-dependent protein kinases during apoptosis. Proc Natl Acad Sci U S A, 1994. 
91(9): p. 3754-8. 
141. Fukuda, S., P. Singh, A. Moh, M. Abe, E.M. Conway, H.S. Boswell, S. 
Yamaguchi, X.Y. Fu, and L.M. Pelus, Survivin mediates aberrant hematopoietic 
progenitor cell proliferation and acute leukemia in mice induced by internal-
tandem-duplication of Flt3. Blood, 2009. 
142. Kelly, L.M., Q. Liu, J.L. Kutok, I.R. Williams, C.L. Boulton, and D.G. Gilliland, 
FLT3 internal tandem duplication mutations associated with human acute 
myeloid leukemias induce myeloproliferative disease in a murine bone marrow 
transplant model. Blood, 2002. 99(1): p. 310-8. 
143. Zhou, B.B., H. Li, J. Yuan, and M.W. Kirschner, Caspase-dependent activation of 
cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl 
Acad Sci U S A, 1998. 95(12): p. 6785-90. 
144. Alam, A., L.Y. Cohen, S. Aouad, and R.P. Sekaly, Early activation of caspases 
during T lymphocyte stimulation results in selective substrate cleavage in 
nonapoptotic cells. J Exp Med, 1999. 190(12): p. 1879-90. 
145. Plescia, J., W. Salz, F. Xia, M. Pennati, N. Zaffaroni, M.G. Daidone, M. Meli, T. 
Dohi, P. Fortugno, Y. Nefedova, D.I. Gabrilovich, G. Colombo, and D.C. Altieri, 
Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005. 7(5): 
p. 457-68. 
146. Chandele, A., V. Prasad, J.C. Jagtap, R. Shukla, and P.R. Shastry, Upregulation 
of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance 
in staurosporine-induced apoptosis. Neoplasia, 2004. 6(1): p. 29-40. 
 
 102 
 
147. Jones, M.K., O.R. Padilla, N.A. Webb, and M. Norng, The anti-apoptosis protein, 
survivin, mediates gastric epithelial cell cytoprotection against ethanol-induced 
injury via activation of the p34(cdc2) cyclin-dependent kinase. J Cell Physiol, 
2008. 215(3): p. 750-64. 
148. Banks, D.P., J. Plescia, D.C. Altieri, J. Chen, S.H. Rosenberg, H. Zhang, and S.C. 
Ng, Survivin does not inhibit caspase-3 activity. Blood, 2000. 96(12): p. 4002-3. 
149. Li, C., Z. Wu, M. Liu, M. Pazgier, and W. Lu, Chemically synthesized human 
survivin does not inhibit caspase-3. Protein Sci, 2008. 
150. Wright, M.E., D.K. Han, and D.M. Hockenbery, Caspase-3 and inhibitor of 
apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian 
cells. FEBS Lett, 2000. 481(1): p. 13-8. 
151. Shin, S., B.J. Sung, Y.S. Cho, H.J. Kim, N.C. Ha, J.I. Hwang, C.W. Chung, Y.K. 
Jung, and B.H. Oh, An anti-apoptotic protein human survivin is a direct inhibitor 
of caspase-3 and -7. Biochemistry, 2001. 40(4): p. 1117-23. 
152. Tewari, M., L.T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D.R. Beidler, G.G. 
Poirier, G.S. Salvesen, and V.M. Dixit, Yama/CPP32 beta, a mammalian 
homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death 
substrate poly(ADP-ribose) polymerase. Cell, 1995. 81(5): p. 801-9. 
153. Leach, S.D., C.D. Scatena, C.J. Keefer, H.A. Goodman, S.Y. Song, L. Yang, and 
J.A. Pietenpol, Negative regulation of Wee1 expression and Cdc2 
phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res, 
1998. 58(15): p. 3231-6. 
154. Wang, F., Y. Zhu, Y. Huang, S. McAvoy, W.B. Johnson, T.H. Cheung, T.K. 
Chung, K.W. Lo, S.F. Yim, M.M. Yu, H.Y. Ngan, Y.F. Wong, and D.I. Smith, 
Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA 
damage-induced apoptosis. Oncogene, 2005. 24(24): p. 3875-85. 
155. Satyanarayana, A., M.B. Hilton, and P. Kaldis, p21 Inhibits Cdk1 in the Absence 
of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint. Mol Biol Cell, 
2008. 19(1): p. 65-77. 
156. Gervais, J.L., P. Seth, and H. Zhang, Cleavage of CDK inhibitor p21(Cip1/Waf1) 
by caspases is an early event during DNA damage-induced apoptosis. J Biol 
Chem, 1998. 273(30): p. 19207-12. 
 
 
 
  
 
CURRICULUM VITAE 
 
Javier Rivera Guzmán 
 
Education: 
 
Ph.D. Microbiology & Immunology, August 2009 
Indiana University, earned at Indiana University-Purdue University at Indianapolis  
 
B.Sc. Biology, May 2002 
Inter American University of Puerto Rico, San German, Puerto Rico 
 
Research and Training Experience: 
 
Indiana University School of Medicine, September 2006 to August 2009 
Graduate Student, Department of Microbiology & Immunology 
Research focus: investigation of the cross-regulatory loop between Survivin and the 
p34Cdc2 kinase, specifically within hematopoietic cells. 
 
Indiana University School of Medicine, March 2003 to September 2006 
Graduate Student, Department of Microbiology & Immunology 
Research focus: investigation of prostate cancer progression due to two essential factors, 
Early Growth Response 1 protein (Egr-1) and the transcription factor and serine 
transmembrane protease Hepsin.  Specifically evaluated the transactivation of Hepsin via 
Egr-1 and its effect on prostate cancer cellular growth.   
 
Indiana University Purdue University Indianapolis (IUPUI) Summer Research 
Opportunities Program, June 2002 to August 2002 
Fellow, Indiana University School of Medicine-Department of Infectious Diseases.   
Research focus: attempting to elucidate the function of the HPV E1^E4 protein by 
creating a GFP-E1^E4 fusion protein, transfecting it into NIK cells and determining its 
intracellular localization. 
 
Inter American University of Puerto Rico, June 2001 to May 2002   
Undergraduate McNair Scholar 
Research focus: field research with Robin Walker, M.Sc., in the Guánica Dry Forest 
International Biosphere studying throughfall and stemflow nutrient cycling in this 
ecosystem. 
 
 
 
 
  
 
Publications: 
 
 Rivera Guzman J, Fukuda S and Pelus LM.  2009.  Inhibition of caspase-3 by 
Survivin Prevents Wee1 Kinase Degradation and Promotes Cell Survival by Maintaining 
Phosphorylation of p34Cdc2.  Manuscript Accepted with Minor Revision. 
 
Mayo LD, Rok Seo Y, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar 
CK, Donner DB.  2005. Phosphorylation of human p53 at serine 46 determines promoter 
selection and whether apoptosis is attenuated or amplified.  Journal of Biological 
Chemistry 280(28):25953-9. 
 
Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo L, Li Q, Rivera Guzman J, 
Korgaonkar CK, Donner DB.  2004.  Cell type specific expression of the IkB kinases 
determines the significance of PI 3-kinase/Akt signaling to NF-kB activation.  Journal of 
Biological Chemistry 279(3):1615-20. 
 
Conferences Attended: 
 
November 2008, ABRCMS (Annual Biomedical Research Conference for Minority 
Students), Indiana University recruitment officer, Orlando, FL 
 
June 2008, AGEP Colloquim Postdoctoral Bootcamp, San Francisco, CA 
 
Rivera Guzman J., Fukuda S. and Pelus L.M.  2007.  Survivin Inhibition of p34Cdc2 Via 
Protection of Wee1 Correlates with Survival.  Blood 110(11), ASH Meeting Supplement: 
p.984A. Abstract Published.  Poster presented at the American Society of Experimental 
Hematology (ASH) annual meeting, December 7-11 in Atlanta, GA  
 
Rivera Guzman J., Fukuda S. and Pelus L.M.  2007. Survival Crosstalk: Survivin 
Inhibition of p34Cdc2.  Poster and oral presentations at the St Jude Childrens Research 
Hospital National Graduate Student Symposium meeting in Memphis, Tennessee   
Rivera Guzman J., Fukuda S. and Pelus L.M.  2006.  Survivin Increases Inhibition of  
p34Cdc2 – Another Putative Anti-Apoptotic Mechanism.  Experimental Hematology 
34(9), Supplement 1: p81.  Abstract Published. Poster presented at the International 
Society of Experimental Hematology (ISEH) meeting, September 2006 in Minneapolis, 
MN 
 
June 2005, Preparing Future Faculty STEM Summer Institute Conference, El Paso, TX  
 
November 2004, Autumn Immunology Conference, Chicago, CA 
 
October 2004, 57th Annual Symposium on Fundamental Cancer Research, Houston, TX 
  
 
 
April 2004, American Association for Higher Education Conference, San Diego, CA 
 
August 2002, Summer Research Opportunities Program Research Conference, Penn State 
University, College Park, PA 
 
November 25, 2001 to December 2, 2001, 4th International Symposium of Sustainable 
Development in the Andes, Merida, Venezuela 
 
Honors, Awards and Fellowships: 
 
IU Nominee and Selected Attendee, Summer AGEP Colloquim Postdoctoral Bootcamp, 
June 2008 University of California San Francisco 
 
St Jude Children’s Research Hospital Fellowship, National Graduate Student 
Symposium, March 2007 Memphis, TN 
 
Selected Abstract Travel Award, International Society of Experimental Hematology 
Conference, September 2006, Minneapolis, MN 
 
John Wallace Minority Travel Scholarship, Autumn Immunology Conference, November 
2004 Chicago, IL 
 
Gene Therapy Training Grant, Indiana University School of Medicine NIH pre-Doctoral 
Fellow, T32 from NHLBI (HL007910), July 2004 to June 2009 
Conference and Travel Award, American Association for Higher Education Hispanic 
Caucus Conference Fellow, April 2004, San Diego, CA 
 
NIH pre-Doctoral Fellow, T32 from NIDDK, Hematopoiesis Training Program, July 
2003 to June 2004, Indiana University School of Medicine, Indianapolis, IN 
 
Graduated Ronald E. McNair Scholar, McNair Scholars Program, Inter American 
University of Puerto Rico, San German, PR 
 
Graduated Magna Cum Laude, Inter American University of Puerto Rico, San German, 
PR 
 
1st Place Oral Presentations, Ronald E. McNair Summer Training Program Forum, 
August 2001, Inter American University of Puerto Rico 
 
 
 
  
 
Professional Experience: 
 
Preparing Future Faculty Institute, Indiana University-Purdue University Indianapolis.  
Full-day seminar series on faculty preparation and duties, June 2008 
 
Ad hoc member (Senior Graduate Student), Advisory Committee 
NIH NIGMS 1R25 GM079657-01 (Hal Broxmeyer, PI), Indiana University School of 
Medicine Initiative for Maximizing Graduate Student Diversity, January 2007 
Indianapolis, IN 
 
Indiana University School of Medicine, Indianapolis, IN- June 2006 to July 2006 
Instructor-Medical Spanish for Medical Students 
Planned lessons, created teaching materials, and coordinated an interactive clinical 
scenario simulation review session.   
 
President, IUPUI Under-represented Professional and Graduate student Organization 
(UPNGO), January 2006 to August 2006, Indianapolis, IN 
 
Preparing Future Faculty STEM Summer Institute Conference at the University of Texas 
at El Paso, June 2005 
 
Indiana University Department of Microbiology & Immunology, Indianapolis, IN-
January 2004-May 2004 
Teaching Assistant-Medical Microbiology for the Nursing Program  
Taught one lab section; helped proctor and grade lecture exams. 
 
President of the  Chapter of the  Biological Honor Society, August 2001 to May 
2002, Inter American University of Puerto Rico 
 
Vice-President of the  Chapter of the  Biological Honor Society, January 2001 to 
July 2001, Inter American University of Puerto Rico 
 
 
 
